AU703744B2 - Pyridinone-thrombin inhibitors - Google Patents
Pyridinone-thrombin inhibitors Download PDFInfo
- Publication number
- AU703744B2 AU703744B2 AU63917/96A AU6391796A AU703744B2 AU 703744 B2 AU703744 B2 AU 703744B2 AU 63917/96 A AU63917/96 A AU 63917/96A AU 6391796 A AU6391796 A AU 6391796A AU 703744 B2 AU703744 B2 AU 703744B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- pyridinone
- mmol
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Pyridinone thrombin Inhibitors Background of the Invention Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.
Edwards et al., J. Amer. Chem. Soc. (1992) Vol. 114, pp. 1854-63, describes peptidyl a-ketobenzoxazoles which are reversible inhibitors of the serine proteases human leukocyte elastase and porcine pancreatic elastase.
European Publication 363 284 describes analogs of peptidase substrates in which the nitrogen atom of the scissile amide group of the substrate peptide has been replaced by hydrogen or a substituted carbonyl moiety.
European Publication 195 212 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or ca-keto carboxyl derivatives.
R.J. Brown et al., J. Med. Chem. Vol. 37, pages 1259-1261 (1994) describes orally active, non-peptidic inhibitors of human leukocyte elastase which contain trifluoromethylketone and pyridinone moieties.
I-I. Mack et al., J. Enzyme Inhibition Vol 9, pages 73-86 (1995) describes rigid amidino-phenylalanine thrombin inhibitors which contain a pyridinone moiety as a central a 20 core structure.
S**
Summary of the Invention The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the 25 invention in a pharmaceutically acceptable carrier. These compositions may optionally include anticoagulants, antiplatelet agents, o* a. 0 INA.I .I3IPI0347 isd WO 97/01338 PCT/US96/10778 -2and thrombolytic agents. The compositions can be added to blood, blood products, or mammalian organs in order to effect the desired inhibitions.
The invention also includes a composition for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.
The invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.
Some abbreviations that may appear in this application are as follows.
ABBREVIATIONS
Designation BOC (Boc) CBZ (Cbz) TBS (TBDMS) Activating Group HBT(HOBT or HOBt) Designation BOP reagent
BOP-CI
EDC
Protecting Group t-butyloxycarbonyl benzyloxycarbonyl(carbobenzoxy) t-butyl-dimethylsilyl 1-hydroxybenzotriazole hydrate Coupling Reagent benzotriazol-l-yloxytris- (dimethylamino)phosphonium hexafluorophosphate bis(2-oxo-3-oxazolidinyl)phosphinic chloride 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride I-I I Cq L (BOC)2O (BOC 1
,O)
n-Bu 4 N FnBuLi (N-Buli)
DMF
Et 3
N
EtOAc:
TFA
DMAP
DME
LDA
DPPA
THF
DIPEA
Other di-t-butyl dicarhonate tetrabutyl ammonium fluoride n-butyllithiurn d imethyl formamide triethylamine ethyl acetate ,rifluoroacetic acid dimethylaminopyridine d imethoxyethane lithiumn diisopropylamide diphenyiphosphoryl azide tetrahydrofuran diisopropylethylamine 20 0* Ile Phe Pro Ala Val Amino Acid Isoleucine Phenylalanine Proline Alani ne Valine .e b
C
C*
C
Detailed Description of the Invention and Preferred Embodiments Compounds of the invention are useful as thrombin inhibitors and have therapeutic v'alue in for example, preventing coronary artery disease.
According to a First embodiment or the invention there is provided a compound 25 having the formula 0
H
CC
C
CCC C C. C C wherein W is R1OCO,
RICO,
RISO
2 (Rl)m,(CH 2 ),,NHqC0, where n is 0-4, m is Ior 2, and q is 0 or 1, I N L BUT034 1 4 with the proviso that where n is 1-4, qj is 1 and m is 1, and where n is 0, in is I or 2, and q isO0 or 1, and with the further proviso that where n is 0, mi is 2 and (I is 0, RI can be the same or different; R, is
R
2
(CH
2 where n is 0-4,
(R
2
)(OR
2
)CH(CH
9 where p is 1-4,
(R
2 2 CH-(CH), where n is 0-4 and R 2 can be the same or different, and wherein
(R
2 2 can also be a ring substituent on CHI represented by C 3 7 cycloalkyl, C 7 12 bicyclic lo alkyl, or a 5- to 7-mernbered mono- or bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to three heteroatoms selected fromn the group consisting of N, 0 and S, and
R
2
O(CH
2 7)p, wherein p is 1-4;
R
2 is hydrogen, phenyl, unsubstituted or substituted with one or more Of C 1-4 linear Or branched alkyl, C 1 4 linear or branched alkoxy, halogen, trifluoroinethyl. hydroxv, C0011, or
CONH,
naphthyl, biphenyl, a 5- to 7-memnbered mono- or a 9- to lO-ruembered bicyclic heterocyclic ring which can be saturated or unsaturated, WO 97/01338 PCT/US96/10778 and which contains from one to three heteroatoms selected from the group consisting of N, O and S,
COOR
6 Cl-4 linear or branched alkyl, C3-7 cycloalkyl, or C7-12 bicyclic alkyl;
R
3 is hydrogen, Cl-4 linear or branched alkyl, C3-7 cycloalkyl, or trifluoromethyl; A is chosen from one of the following Radicals:
NH
YH
N H 2 NH2
N,{
trans R 4 II III IV wherein R 4 and R 5 are independently H, Cl-4 linear or branched alkyl or alkoxy; C3-C7 cycloalkyl; halogen; or trifluoromethyl; Y is hydrogen, hydroxy, or
CN;
R
6 is hydrogen, or Cl-4 linear or branched alkyl, and pharmaceutically acceptable salts thereof.
r III I 1 WO 97/01338 PCT/US96/10778 -6- A useful class of compounds is the embodiment wherein W is R or R 1S02. A further useful subclass of compounds is the embodiment wherein R 1 is R 2 (CH2)n, (R 2 )2CH(CH2)n, phenyl, or (phenyl)2-CH.
Another useful class of compounds is the embodiment wherein R 3 is C1-4 linear or branched alkyl and particularly wherein R 3 is methyl.
Another useful class of compounds is the embodiment wherein R 4 is Cl-4 linear or branched alkyl and R 5 is methyl or hydrogen and particularly wherein R 4 is methyl and R 5 is methyl or hydrogen and most particularly when R 4 is methyl and R 5 is hydrogen.
In one exemplification of the invention, W is R 1 S02 and A is Radical II (in which both configurations of the trans radical are contemplated within the scope of this invention). Specific embodiments of this class include (note that the methyl group is conventionally indicated as a single bond attached to a ring): 0 ,NH 2 H O H 2 SN
N
and O r ,,NH2 c i L I WO 97/01338 WO 9701338PCTJUS96/10778 H 0 H "eOH 02 In another exemplification of the invention, W is R 1 S02 and III. Specific embodiments of this class include: A is Radical
N~NH
2
H
NjX s-
'N
0
NH
2 N NN 0 0 H
NH
2 N N N N
NH
2
S'
I 02 WO 97/01338 WO 9701338PCTIUS96/10773 -8-
NH
2
CI
H
Ck s
NH
2
H
N3 3:NyNH 2 11 'N
N
In a third exemplification of the invention, W is R 1 S02 and A is Radical WV. Specific embodiments of this class include:
NH
2 ILH
HNH
S'N N N "r 02 0
NH
2 Hi N
-L-
S 'NI 02 1 0
I
WO 97/01338 PCT/US96/10778 -9- N2 H H N
NH
N N
N
02 0 The compounds of the present invention, may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. A racemate or racemic mixture does not imply a 50:50 mixture of stereoisomers.
When any variable occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl); "alkoxy" represents an alky! group of indicated number of carbon atoms attached through an oxygen bridge; "Halo", as used herein, means fluoro, chloro, bromo and iodo; and "counterion" is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate, trifluoroacetate, perchlorate, nitrate, benzoate, maleate, sulfate, tartrate, hemitartrate, benzene sulfonate, and the like.
The term "C3-7cycloalkyl" is intended to include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl anjd cycloheptyl, and the like.
The term "C7-12 bicyclic alkyl" is intended to include bicyc!o[2.2.1]heptyl (norbornyl), bicyclo[2.2.2]octyl, 1,1.3-trimethylbicyclo[2.2.1]heptyl (bornyl), and the like.
I e WO 97/01338 PCTIUS96/10778 The term "heterocycle" or "heterocyclic ring", as used herein except where noted, represents a stable 5- to 7-membered mono- or bicvclic or stable 7- to 10-membered bicyclic heterocyclic ring system any ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
Especially useful are rings containing one oxygen or sulfur, one to three nitrogen atoms, or one oxygen or sulfur combined with one or two nitrogen atoms. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
Examples of such heterocyclic groups include piperidinyl, piperazinyl, 2oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, iscthiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl. Morpholino is the same as morpholinyl.
The pharmaceutically-acceptable salts of the compound., of Formula I (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts or the quatemary ammonium salts which are formed, from inorganic or organic acids or bases.
Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesuifonate, lactate, maleate, ~s 1 ~I I~LbPI methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-Dglucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butylchloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl. lauryl, myristyl and stearyl chlorides, bromides cand iodides, aralkyl halides like benzyl and phenethyl bromides and others.
Thrombin inhibitors therapeutic uses and methods of using Anticoagulant therapy is indicazed for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy. The term "patient" used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, and mice.
Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood coagulation is S. 20 required such as to prevent coagulation of stored whole blood and to prevent ilation S" in other biological samples for testing or storage. Thus, the thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems.
SAccording to a second embodiment of the invention, there is provided a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier.
According to a third embodiment of the invention, there is provided method for inhibiting thrombin in blood in a mammal requiring said inhibition, comprising adding to the blood of said mammal a compound of the first embodiment or a composition according to the second embodiment.
According to a fourth embodiment of the invention, there is provided a method for inhibiting formation of blood platelet aggregates in blood in a mammal requiring said inhibition, comprising adding to the blood of said mammal a compound of the first embodiment or a composition of the second embodiment in an amount which effectively inhibits said blood platelet aggregate formation.
According to a fifth embodiment of the invention, there is provided a method for inhibiting thrombus formation in blood in a mammal requiring said inhibition, comprising 11a adding to the blood of said mammal a compound of the first embodiment or a composition of the second embodiment in an amount which effectively inhibits said thrombus formation.
According to a sixth embodiment of the invention, there is provided the use of a s compound of the first embodiment or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for inhibiting thrombin, inhibiting thrombus formation, treating thrombus formation, or preventing thrombus formation in a mammal.
According to a seventh embodiment of the invention, there is provided a compound of the first embodiment or a pharmaceutically acceptable salt thereof when used for the inhibition of thrombin, inhibition of thrombus formation, the treatment of thrombus formation, or the prevention of thrombus formation in a mammal requiring said inhibition, treatment or prevention.
The thrombin inhibitors of the invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, ib IN L [I'FFI0 347 kml WO 97/01338 PCT/US96/10778 12tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.
The thrombin inhibitors can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Coming Corporation.
The thrombin inhibitors can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
The thrombin inhibitors may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The thrombin inhibitors may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinlypyrrolidone, pyran copolymer, polyhydroxy-propylmethacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
Furthermore, the thrombin inhibitors may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
I I M WO 97/01338 PCT/US96/10778 -13- "The dosage regimen utilizing the thrombin inhibitors is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.
Oral dosages of the thrombin inhibitors, when used for the indicated effects, will range between about 0.1 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably 1.0-100 mg/kg/day and most preferably 1-20 mg/kg/day. Intravenously, the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, the thrombin inhibitors may be administered in divided doses of two, three, or four times daily.
Furthermore, they can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, or course, be continuous rather than intermittent throughout the dosage regime.
The thrombin inhibitors are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixers, syrups and the like, and consistent with convention pharmaceutical practices.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, nontoxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as I I L- _1 WO 97/01338 PCT/US96/10778 -14ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, distintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, cornsweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearatc, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.
The thrombin inhibitors can also be co-administered with suitable anti-coagulation agents or thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various ascular pathologies. For example, thrombin inhibitors enhance the efficiency of tissue plasminogen activatormediated thrombolytic reperfusion. Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter. They may also be combined with heparin, aspirin, or warfarin.
Methods of making The following synthetic Methods A to E can be used to prepare the compounds of the present invention.
Two methods for preparing compounds which contain radical IV as an end group are illustrated as Methods A and B and are exemplified by Examples I and XXV.
METHOD A As exemplified by Example 1, methyl-2-hydroxy-6methylpyridinone-3-carboxylate is alkylated with t-butylbromoacetate using a base such as cesium carbonate in DMF, or sodium hydride in THF. The t-butyl group is removed using a strong acid such as HCI gas I M il~ WO 97/01338 PCTUS96/10778 and the amide of 4-aminomethyl-1-t-butoxycarbonylpiperidine is made using a standard coupling procedure. The methyl ester is hydrolyzed with lithium hydroxide and then a Curtius rearrangement (with acyl azide formation using DPPA and triethylamine as the base) gives the isocyanate which is trapped with benzyl alcohol in the presence of triethylamine giving the Cbz protected aminopyridinone. The Cbz group is removed by hydrogenolysis using Pearlman's catalyst under standard conditions. Bis-benzylsulfonylation can be accomplished using benzylsulfonyl chloride and triethylamine in methylene chloride. The BOC group is removed using a strong acid such as HCI gas and amidinopiperidine formation can be performed using an amidine transfer reagent such as aminoiminomethanesulfonic acid with triethylamine as a base in DMF. One of the sulfonyl groups is then removed using aqueous lithium hydroxide.
Amide couplings, Step D in Method A, to form the compounds of this invention can be performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide, or 1-ethyl-3-(3dimethyl-aminopropyl) carbodiimide. Other methods of forming the amide or peptide bond include, but are not limited to the synthetic routes via an acid chloride, azide, mixed anhydride or activated ester.
Typically, solution phase amide couplings are performed, but solid-phase synthesis by classical Merrifield techniques may be employed instead.
The adotion and removal of one or more protecting groups is also typical practice.
Modifications of Methods A to E will allow different W, A and R 3 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step. For example, in the following Method A, the starting pyridine in Step A, can have as the 6substituent, ethyl, isopropyl, cyclopropyl, and the like, to achieve the different operable values of R 3 Likewise, different W groups can be present by the use of an appropriate alkylating, carbonylating, sulfonylating, urealating agent, and the like, in Step H. Use of, for example, an alkyl halide, alkoxycarbonyl halide, acyl halide, s _I I I II WO 97/01338 PCT/US96/10778 16alkylsulfonyl halide, or alkyl isocyanate will yield the corresponding values of W where W is R 1 RIOCO, RICO, R 1 S02, or (R I)m(CH2)nNCO. Likewise, the different Radicals A can be present by the appropriate choice of the radical precursor in Step D. Obvious variations and modifications of the Methods to produce similar and obvious variants thereof, will be apparent to one skilled in the art.
METHOD A H0 2 C MeOH,
HCI
SIN StepA HO NH
H
MeO 2
C
HO'
BrCH 2
CO
2 tBu Cs 2
CO
3
DMF
N Step B
H
MeOC, I-rOH 0 MeO 2
C
HCI, EtOAc Step C H2NNBOC
H
2 MeO 2
C
EDC, HOBT, DIPEA, DMF Step D
NBOC
Step E LiOH, H 2 0, MeOH, THF WO 97/01338 WO 9701338PCTIUS96/10778 17 Method A, Cont'd NBOC DPPA, Et 3 N, BnOH I~BO Step F CbzNH o )N HNBOC 1YN 0
H
2 N 0 N H NBOC lN" 0 H, Pd(OH) 2
/C
EtCH,
H
2 0 Step G BnSO2CCEt 3 N, CH 2
CI
2 Step H Ph~ S A 0~ step 1(i) IHOI, EtOAc
-M
WO 97/01338 WO 9701338PCTIUS96/10778 is- Method A, Cont'd Ph 2 02N 5
HN.H
2
NCSO
3
H
o N N Et 3 N, DMF IrN Step
(H)
0 Ph S02~ Ph~ S N HN 0 N H N NH 2 1YN 0 Step 1(111) LiOH, H 2 0, I MeOH,
THF
H
Ph S'N HN o N H N NH 2 IrN 0 METHOD B Following Method B below, starting 6-methyl-2-hydroxypyridine carboxylic acid is reacted with diphenyiphosphoryl azide (DPPA) and benzyl alcohol in Step A to afford the protected pyridinone.
This is alkylated with a glycine equivalent in Step B such as tbutylbromoacetate using, a base such as cesium carbonate or sodium WO 97/01338 PCT/US96/10778 19hydride. The t-butyl group is removed using a st-ong acid such as HCI gas in Step C and the amide of 4-aminomethyl-l-tbutoxycarbonylpiperidine is made using a standard coupling procedure in Step D. The CBZ group is removed in Step E via hydrogenation over a catalyst. The resulting amine is then reacted with the appropriate reagent, in this case benzylsulfonyl chloride, in Step F with pyridine as an acid scavenger and the BOC group is then removed in Step G using a strong acid such as HCI gas. Amidinopiperidine formation can be performed using an amidine transfer reagent such as aminoiminomethanesulfonic acid with triethylan nt as a ba,;t in DMF. Alternatively the product of step G can be reacted with cyariogen bromide to give the cyanamide in Step H which can be further reacted with hydroxylamine to give the hydroxyguanidine.
Modifications of Method B will allow different W, A and
R
3 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step. For example, in the following Method B, the starting pyridine in Step A, can have as the 6substituent, ethyl, isopropyl, cyclopropyl, and the like, to achieve the different operable values of R 3 Likewise, different W groups can be present by the use of an appropriate alkylating, carbonylating, sulfonylating, urealating agent, and the like, in Step F. Use of, for example, an alkyl halide, alkoxycarbonyl halide, acyl halide, alkylsulfonyl halide, or alkyl isocyanate will yield the corresponding values of W where W is R1, R OCO, R 1 CO, R 1 S2, or (RI)m(CH2)nNCO. Likewise, the different Radicals A can be present by the appropriate choice of the radical precursor in Step D. Obvious variations and modifications of the Method to produce similar and obvious variants thereof, will be apparent to one skilled in the art.
da I I WO 97/01338 WO 9701338PCTIUS96/10778 20 Method B
OPPA,
Et 3 N, BnOH step A CbzNH N
HO"N"
H
BrO H 2 C0 2 tBu 0S 2 00 3
DMF
step B CbzNH HCI, EtOAc step C CbzNH
ON
IrOH 0 EDO, HOET, amine step D
H
2 Pd(OH) 2
/C
EtOH, H 2 0 step E 11
NBOC
H
N
HAN
BnSO 2 CI, pyridine ste p F HCI, EtOAc se step G m WO 97/01338 WO 9701338PCTIUS96/10778 Ph
S,
-21 Method B (Cont'd)
H
~N
o N HNH I
N
0 H N. H 2
NCSO
3 Et 3 N, DMF ,H ste ~p H Ph
H
SN
0
NH
2 IBrCN, MeOH step I
NH
2 OH, MeOH step J Ph
H
K
N
0 N H NON IrN,,C Ph
H
KS,
N
0 0 WO 97/01338 PCT/US96/10778 -22- METHOD C For preparing compounds which contain radical II as an end group one can use the following illustrated Method C. As exemplified by Example II, 2-hydroxy-3-nitro-6-methylpyridine is alkylated with ethylbromoacetate. The methyl ester is hydrolyzed with lithium hydroxide and the amide of trans-4-tbutoxycarbonylaminocyclohexylmethylamine is made using a standard coupling procedure. The nitro group is reduced by hydrogenation using a palladium catalyst under standard conditions. The amino group is alkylated by reduction with sodium triacetoxyborohydride of Jie imine formed from phenylacetaldehyde. The BOC group is removed using a strong acid such as HCI gas.
Modifications of Method C will allow different W, A and
R
3 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step. For example, in the following Method C, the starting pyridine in Step A, can have as the 6substituent, ethyl, isopropyl, cyclopropyl, and the like, to achieve the different operable values of R 3 Likewise, different W groups can be present by the use of an appropriate alkylating, carbonylating, sulfonylating, urealyting agent, and the like, in Step E. Use of, for example, an alkyl aldehyde, alkyl halide, alkoxycarbonyl halide, acyl halide, alkylsulfonyl halide, or alkyl isocyanate will yield the corresponding values of W where W is RI, R 1 OCO, R 1 CO, RIS02, or (RI)m(CH2)nNCO. Likewise, the different Radicals A can be present by the appropriate choice of the radical precursor in Step C. Obvious variations and modifications of the Methods to produce similar and obvious variants thereof, will be apparent to one skilled in the art.
I I IICCL- WO 97/01338 PTU9/07 PCT[US96/10778 23 Method C 0 2
N
HO
BrCH 2 C0 2 Et
CS
2
CO
3
DMF
Step A
O
2 NZ O
N
0 LIOH, H 2 0, MeOH, THF Step B 0 2
N
I-rOH 0 H2N
NHBOC
EDO, HOBT, TEA, DMF Step C 0 2
N
NHBOC
O N
H
I-rN"I r 0
H
2 Pd/C EtOH, AcOH Step D
HBOC
PhCH 2 CHO, Na(ACO) 3
BH
CH
2
CICH
2 CI, AcOH Step E 0 WO 97/01338 PCT/US96/10778 -24- Method C Cont'd r Ph
HN
Ha, NHBOC 0
O
HCI, EtOAc Step F l Ph
.NH
2 METHOD D A method for preparing compounds which contain radical III is illustratea by following Method D and is exemplified by Example V.
In Step A the CBZ group is removed from the product of Method B, Step B via hydrogenation over a catalyst. The resulting amine is then reacted with the appropriate reagent, in this case benzylsulfonyl chloride, in Step B with pyridine as an acid scavenger and the t-butyl ester is then removed under acidic conditions in Step C. The acid is then coupled in Step D with an amine, such as 2-t-butoxycarbonylamino-6-methyl-5aminomethyl pyridine and the BOC group is removed in Step E with a strong acid.
91 WO 97/01338 WO 9701338PCT/US96/10778 25 Method D CbzNH 0
H
2 Pd(OH) 2
/C
EtCH, H 2 0 :-tep A BnSO 2 CI, Pyridine
H
2
N
0 0N
C
step C step B HOI, EtOAc i. DCC, amine, CH 2
CI
2 ii. HOI, EtOAc step E Ph
H
SN
02
NH
2
H
yN
N
0 WO 97/01338 PCT/US96/10778 -26- Modifications of Method D will allow different W, A and R3 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step. For example, the starting pyridinone in Step A, can have as the 6-substituent, ethyl, isopropyl, cyclopropyl, and the like, to achieve the different operable values of R 3 Likewise, different W groups can be present by the use of an appropriate alkylating, carbonylating, sulfonylating, urealyting agent, and the like, in Step B. Use of, for example, an alkyl halide, alkoxycarbonyl halide, acyl halide, alkylsulfonyl halide, or alkyl isocyanate will yield the corresponding values of W where W is R 1 RIOCO, RICO, R 1 S02, or (RI)m(CH2)nNCO. Likewise, the different substituted Radicals IV can be present by the appropriate choice of the substituted radical precursor in Step D. Obvious variations and modifications of the Methods to produce similar and obvious variants thereof, will be apparent to one skilled in the art.
METHOD E For preparing compounds which contain a 6trifluoromethylpyridinone, one can use the following illustrated Method E. As exemplified by Example XXIII, starting butyl-2trifluoroacetylvinyl ether is condensed with nitroacetamide in the presence of a base such as sodium ethoxide in Step A. The resulting pyridinone is allylated using 7t-allyl palladium in Step B and the nitrogroup is reduced in Step C. The amine is then reacted with the appropriate reagent, in this case benzylsulfonyl chloride, in Step D with pyridine as an acid scavenger. The olefin is oxidatively cleaved to give the aldehyde which is further oxidised to the acid in Step E. The acid is then coupled in Step F with an amine, such as 2-t-butoxycarbonylaminopyridine and the BOC group is removed with a strong acid.
I II Il T~ WO 97101338 WO 97O1338PCTIIJS96/10778 27 Method E TFAA, Py 0 step A NaQEt, EtCH
O
2
NCH
2
CONH
2 step B 0 0
CF
3 0 2
N
HO N CF 3 step C Pd(OAc) 2 Ph 3
P
AcO.
H
2
N
ON ICF 3 BnSO 2 CI, PY step E SnCI 2
HOI
step D 0 2
N
O: NCF 3 Ph
H
K-
N
O N C F 3 step F i. RuCI 3 NaIO 4 ii. Cr0 3
H
2 S0 4 ftu WO 97/01338 PCT/US96/10778 -28- Method E (cont'd) h
H
S'N i. DCC, amine
S
2 ii. HCI, EtOAc O N CF 3 st I step G Ph H CO 2
H
02 J
H
N N Modifications of Method E will allow different W and A groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step. For example, different W groups can be present by the use of an appropriate alkylating, carbonylating, sulfonylating, urealyting agent, and the like, in Step E. Use of, for example, an alkyl halide, alkoxycarbonyl halide, acyl halide, alkylsulfonyl halide, or alkyl isocyanate will yield the corresponding values of W where W is R 1 R OCO, RICO, R 1 SO2, or (RI)m(CH2)nNCO. Likewise, the different substituted Radicals A can be present by the appropriate choice of the substituted radical precursor in Step G. Obvious variations and modifications of the Method to produce similar and obvious variants thereof, will be apparent to one skilled in the art.
-I
WO 97/01338 PCT/US96/10778 -29- The following examples are illustrative of the invention as contemplated by the inventors and should not be construed as being limits on the scope or spirit of the instant invention.
Note that the NMR field strength employed in the below given examples was either 300 or 400 MHz.
EXAMPLE 1 Preparation of 3-Benzylsulfonylamino-6-methyl- I -(4-methylenecarboxamidomethyl-l-amidinopiperidinyl)-2-pyridinone
NH
2 H
H
N N
N
Step A: Methyl-2-hydroxy-6-methylpyridine-3-carboxylate Acetyl chloride (50 ml) was added cautiously to a stirred suspension of 2-hydroxy-6-methylpyridine-3-carboxylic acid (14.3 g, 93.44 mmol) in dry methanol (500 ml) and the resulting solution was heated to reflux. After 16 h the solution was evaporated in vacuo to give the title compound (15.62 g, 100%) as a solid: IH NMR (DMSO) shows the methyl singlet at 5 3.71.
Step B: Methyl-6-methyl-l(t-butyl-methylenecarboxy)-2pyridinone-3-carboxylate t-Butylbromoacetate (13.8 ml, 93.46 mmol) was added to a stirred suspension of methyl-2-hydroxy-6-methylpyridine-3-carboxylate (15.62 g, 93.44 mol) and cesium carbonate (30.44 g, 93.43 nimol) in dry DMF (180 ml). After 64 h, the reaction was evaporated in vacuo to a thick paste which was partitioned between ethyl acetate and brine, adding enough water to dissolve all the salts. The organic layer was dried (Na2SO4) and evaporated in vacuo. The resulting material was purified by flash column chromatography on silica (ethyl acetate/hexanes WO 97/01338 PCT/US96/10778 gradient, 30-50% ethyl acetate) to give the title compound (8.2 g, 31%) as a foam: IH NMR (CDC13) 5 1.48 9 2.35 3 3.88 3 4.76 2 6.14 J 7.5 Hz, 1H), 8.12 J 7.5 Hz, 1H).
Step C: Methyl-6-methyl-1 -methylenecarboxy-2-pyridinone-3carboxylate HCI gas was bubbled through a stirred solution of methyl-6methyl-1 (t-butyl-methylenecarboxy)-2-pyridinone-3-carboxylate (8.2 g, 29.1 mmol) in ethyl acetate/methylene chloride (40 ml) at 0°C for min. After 1 hour, the solution was warmed to RT and after a further min the solution was degassed with argon and was evaporated in vacuo to give the title compound (6.37 g, 73%) as a solid: 1H NMR (CDC13) 5 2.28 3H), 3.72 3H), 4.69 2H), 6.12 J 7.5Hz, lH), 8.13 (d,J 7.5Hz, 1H).
Step D: Methyl-6-methyl- -(4-methylenecarboxamidomethyl- 1t-butoxycarbonylpiperidinyl)-2-pyridinone-3-carboxylate EDC hydrochloride (2.34 g, 12.18 mmol) was added to a stirred mixture of methyl-6-methyl- -methylenecarboxy-2-pyridinone-3carboxylate (2.0 g, 8.88 mmol), 4-aminomethyl-l-t-butoxycarbonylpiperidine (3.0 g, 14.21 mmol), HOBT (1.65 g, 12.18 mmol) and diisopropylethylamine (3.6 ml, 10.30 mmol) in dry DMF (20 ml). After 16 h the reaction was diluted with ethyl acetate and was washed with 10% citric acid solution, water, saturated sodium hydrogen carbonate solution and brine, dried (MgSO4) and evaporated in vacuo to give the title compound (3.0 g, 80%) as a foam: 1H NMR (CDC13) selected signals at 5 1.44 9H, t-Bu), 3.89 3H, OMe), 7.11 (brt, J 5.3Hz, IH, NH).
Step E: 6-Methyl-1 -(4-methylenecarboxamidomethyl-1 -tbutoxy-carbonylpiperidinvl)-2-pyridinone-3-carboxylic acid Lithium hydroxide (8.23 ml of 1 M aqueous solution) was added to a stirred solution of methyl-6-methyl- l-(4-methylenecarbox- -r 1-_ WO 97/01338 PCT/US96/10778 -31 amidomethyl- -t-butoxycarbonylpiperidinyl)-2-pyridinone-3-carboxylate (2.31 g, 5.48 mmol) in 1:1 methanol/THF (16 ml). After 16 h the reaction was concentrated in vacuo to remove the volatiles, and the resulting mixture was partitioned between ethyl acetate and 10% citric acid solution. The organic layer was washed with brine, dried (MgSO4) and evaporated in vacuo to give the title compound (2.0 g, 90%) as a foam: 1H NMR (CDC13) shows loss or the methyl singlet at 6 3.89.
Ste F: 3-Benzyloxycarbonylamino-6-methyl-1 -(4-methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2pyridinone DPPA (1.53 ml, 7.11 mmol) was added to a stirred solution of 6-methyl-1 -(4-methylenecarboxamidomethyl- I-t-butoxycarbonylpiperidinyl)-2-pyridinone-3-carboxylic acid (1.93 g, 4.74 mmol) and triethylamine (0.99 ml, 7.11 mmol) in dry dioxane (10 ml) and the resulting solution was heated to reflux. After 48 h more triethylamine (0.99 ml, 7.11 mmol) and benzyl alcohol (0.74 ml, 7.11 mmol) were added and the solution was refluxed for a further 24 h. The reaction was partitioned between ethyl acetate and 10% citric acid, and the organic layer was washed with water, sodium hydrogen carbonate solution and brine, dried (MgSO4) and evaporated in vacuo to a foam. The crude product was purified by flash column chromatography (80% ethyl acetate/hexanes) to give the title compound (1.53 g, 63%) as a foam: 1
H
NMR (CDC13) selected signals at 6 5.21 2H, PhCH2), 7.33-7.41 (m, 5H, Ph), 7.69 (br s, 1H, CbzNH).
Step G: 3-Amino-6-methyl-1 -(4-methylenecarboxamidomethyl- 1t-butoxycarbonylpiperidinyl)-2-pyridinone A mixture of 3-Benzyloxycarbonylamino-6-methyl- 1-(4methylenecarboxamidomethyl-1 -t-butoxycarbonylpiperidinyl)-2pyridinone (0.50 g, 0.975 mmol) and Pearlman's catalyst (200 mg) in 5:1 ethanol/water (60 ml) was stirred under H2 (balloon) for 16 h. The reaction mixture was filtered through celite and evaporated in vacuo to give the title compound (0.385 g) as a foam: 1 H NMR (CDC13) see I r~ i IC c I WO 97/01338 PCT/US96/10778 -32disajpearance of the Cbz protons. Selected signals at 6 5.99 (dJ 7.3 Hz, 1H, pyridinone 6.54 J 7.3Hz, 1H, pyridinone H-4).
Step H: 3-N,N-(Bis-benzylsulfonyl)amino-6-methyl-1-(4methylenecarboxamidomethyl -1 -t-butoxycarbonylpiperidinvl)-2-pyridinone Benzylsulfonyl chloride (51 mg, 0.27 mmol) was added to a stirred solution of 3-amino-6-methyl- -(4-methylenecarboxamidomethyl- 1-t-butoxycarbonylpiperidinyl)-2-pyridinone (68 mg, 0.18 mmol) and triethylamine (0.075 ml, 0.54 mmol) in dry methylene chloride (0.5 mi).
After 16 h the reaction was loaded directly onto silica and was purified by flash column chromatography (80% ethyl acetate/hexanes) to give the title compound (30 mg, 24%) as a foam: 1 H NMR (CDCI3) selected signals at 5 4.69 2 H, CH2CO), 4.71 J 13.7Hz, 2H, PhCHAHB), 5.17 J 13.7Hz, 2H, PhCHAHB), 5.80 (coalescing AB system, 2H, pyridinone 7.40-7.49 (mn, 1OH, Ph's).
Step I: 3-Benzylsulfonylamino-6-methyl- I -(4-methylenecarboxamidomethyl- I -amidinopiperidinl)-2-pvridinone HCI Gas was bubbled through a solution of 3-N,N-(Bisbenzylsulfonyl)amino-6-methyl- I -(4-methylenecarboxamnidomethyl- I -tbutoxycarbonylpiperidinyl)-2-pyridinone (30 mg, 0.044 mmol) in 1:1 methylene chloride/ethyl acetate (2 ml) for 5 min at OoC. After a further I h the solution was degassed with argon and was evaporated in vacuo to a glass. The resulting material was dissolved in DMF (0.5 mi) and aminoiminomethanesulfonic acid (11 mg) and triethylamine (0.025 ml) were added. After 48 h the reaction was evaporated in vacuo and then was dissolved in 1:1 methanol/THF (2 ml) and I M LiOH (1 ml) was added. After 3 h the reaction was concentrated in vacuo and the crude product purified by preparative HPLC (C 18, 0.1 TFA/H20,CH3CN gradient) to give the title compound (15.9 mg, 61%) as a glass: 1 H NMR 6 1.25 (min, 2 1.84 (min, 3H), 2.33 3H), 3.04 (mn, 2H), 3.16 2H), 3.87 (br d, J 13.7Hz, 2H), 4.45 2H), 4.79 2 6.15 J WO 97/01338 PCT/US96/10778 -33 7.5Hz, 1H), 7.28-7.32 6H), 8.34 (br m, 1H); MS (FAB) 475 EXAMPLE II Preparation of 3-(2-Phenylethylamino)-6-methyl- 1-(methylenecarboxamido-trans-4-aminocyclohexylmethyl 2 -pyridinone H 0
H
N N Step A: 3-Nitro-6-methvl-1 (ethyl-methylenecarboxy)-2-pyridinone Ethylbromoacetate (0.61 ml, 5.5 mmol) was added to a stirred suspension of 3-nitro-2-hydroxy-6-methylpyridine (0.77 g, mmol) and cesium carbonate (1.63 g, 5.0 mmol) in dry DMF (10 ml).
After 16 h, the reaction was acidified with 1 M HCI and was extracted into ethyl acetate, washed with sodium hydrogen carbonate solution and brine, dried (Na2SO4) and evaporated in vacuo to a gum. The crude product was purified by flash column chromatography on silica (ethyl acetate/hexanes gradient, 20-70% ethyl acetate) to give the title compound (0.45 g, 37%) as a foam: 1H NMR (CDC13) 8 1.31 J 7.1Hz, 3H), 2.44 3H), 4.26 J 7.1 Hz, 2H), 4.88 2H), 6.22 J 7.9Hz, 1H), 8.33 J 7.9Hz, 1H).
Step B: 3-Nitro-6-methvl-1 -methylenecarboxy-2-pyridinone Lithium hydroxide (86 mg, 2.05 mmol) was added to a stirred solution of 3-Nitro-6-methyl-1 (ethyl-methylenecarboxy)-2pyridinone (0.45 g, 1.86 mmol) in 1:1:1 methanol/THF/water (6 ml).
After 64 h the reaction was diluted with sodium hydrogen carbonate solution and was washed with methylene chloride (3 times). The aqueous layer was acidified with concentrated HCI to pH 1 and was concentrated in vacuo to the point when sodium chloride started to crystallize from the
_I
WO 97/01338 PCT/US96/10778 -34solution. The mixture was then extracted with ethyl acetate (3 times) and the combined extracts were dried (Na2SO4) and evaporated in vacuo to give the title compound (285 mg, 72%) as a tan solid: 1 H NMR shows loss of the ethyl signals.
Step C: 3-Nitro-6-methyl-l-(methylenecarboxamido-trans-4-tbutoxycarbonylaminocvciohexylmethyl)-2-pyridinone EDC hydrochloride (249 mg, 1.30 mmol) was added to a stirred mixture of 3-nitro-6-methyl-l-methylenecarboxy-2-pyridinone (212 mg, 1.00 mmol), trans-4-t-butoxycarbonylaminocyclohexylmethylamine (228 mg, 1.00 mmol), HOBT (176 mg, 1.30 mmol) and triethylamine (0.18 ml, 1.30 mmol) in dry DMF (4 ml). After 16 h the reaction was diluted with ethyl acetate and was washed with 5% KHSO4 solution, saturated sodium hydrogen carbonate solution and brine, dried (MgSO4) and evaporated in vacuo to a solid. The crude product was purified by flash column chromatography on silica (ethyl acetate/hexanes gradient, 20-40% ethyl acetate) to give the title compound (280 mg, 66%) as a solid: 1 H NMR (CDC13) selected signals at 6 1.43 9H, t-Bu), 3.08 J 6.4Hz, 2H, NHCH2), 3.34 (br s, 1 H, BOCNHCH), 4.35 (br s, 1H, BOCNH), 6.79 (br t, 1H, NHCH2).
Step D: 3-Amino-6-methyl-l -(methylenecarboxamido-trans-4t-butoxycarbonvlaminocyclohexylmethyl)-2-pyridinone A mixture of 3-nitro-6-methyl- -(methylenecarboxamidotrans-4-t-butoxycarbonylaminocyclohexylmethyl)-2-pyridinone (280 mg, 0.66 mmol) and 10% palladium on carbon (29 mg) in 10:1 ethanol acetic acid (I 1 ml) was stirred under hydrogen (balloon) for 16 h. The mixture was filtered through celite and evaporated in vacuo to a semi-solid. The crude product was purified by flash column chromatography on silica (ethyl acetate/hexanes gradient, 70-100% ethyl acetate followed by a chloroform/methanol gradient, 2-8% methanol) to give the title compound (159 mg, 61%) as a pale tan solid: I I -9 ~e 1 WO 97/01338 PCTIUS96/10778 1H NMR (CDCI3) selected signals at 8 4.33 (br s, 1H, NH2), 5.98 J 7.3Hz, 1H), 6.53 J 7.3Hz, 1H).
Step E: 3-(2-Phenylethylamino)-6-methyl- 1 -(methylenecarboxamido-trans-4-t-butoxycarbonylaminocyclohexylmethvl 2-pyvridinone Sodium triacetoxyborohydride (49 mg, 0.23 mmol) was added to a stirred solution of 3-amino-6-methyl- 1 -(methylenecarboxamido-trans-4-t-butoxycarbonylaminocyclo-hexylmethyl)-2pyridinone (60 mg, 0.153 mmol) and phenyl acetaldehyde (0.020 ml, 0.17 mmol) in 0.24 M acetic acid in 1,2-dichloroethane (0.77 ml). After 16 h the mixture was quenched with water and extracted into ethyl acetate. The ethyl acetate layer was washed with sodium carbonate solution and brine, dried (Na2SO4) and evaporated in vacuo to a glass.
The crude product was purified by flash column chromatography on silica (ethyl acetate/hexanes gradient, 20-70% ethyl acetate) to give the title compound (52.7 mg, 69%) as a solid: 1 H NMR (CDCI3) selected signals at 6 2.94 J 7.2Hz, 2H, PhCH2), 3.03 J 6.4Hz, 2H, CONHCH2), 3.32 J 7.2Hz, 2H, PhCH2CH2), 4.81 (br t, IH, CH2CH2NH), 7.22-7.33 5H, Ph).
Step F: 3-(2-Phenylethylamino)-6-methyl- 1 -(methylenecarboxamido-trans-4-aminocvclohexvlmethyvl)-2-pyridinone 3-(2-Phenylethylamino)-6-methyl- I -(methylenecarboxamido-trans-4-t-butoxycarbonylaminocyclohexylmethyl)-2-pyridinone (52.7 mg, 0.106 mmol) was dissolved in ethyl acetate saturated with HCI gas (5 mi). After 30 min the solution was evaporated in vacuo to a yellow solid. The crude product was purified by preparative HPLC (C 18, 0. 1% TFA/H20,CH3CN gradient) to give the title compound (32.4 mg, 46%) as a wax: 1H NMR (CD30D) see disappearance of the BOC group; Anal. (C23H32N402.2.1 TFA. 1.8 H20); HRMS (FAB) calc'd for C23H33N402 397.2604, found 397.2614.
a 1 'P I WO 97/01338 WO 9701338PCTIUS96/10778 36 EXAMPLE m1 Preparation of 3-Benzylsulfonylamino-6-methyl -I -(methylenecarboxanmido-tra-ns-4-a-minocycl ohexylmethyl )-2-pvyridinone
H
0
HH
S' IN J N ~N Step A: 3-Benzylsulfonylamino-6-methyl- 1 (methylenecarboxamido-trans-4-t-butyloxycarbonyl amino-cyclohexylmethyl)-2-pvridinone EDC hydrochloride (50 mg, 0.260 rnmol) was added to a stirred mixture of 3-benzylsulfonylamino-6-methyl- I -methylenecarboxy- 2-pyridinone (73 mg, 0.2 17 mmnol), trans-4-tbutoxycarbonylaminocyclohexylmethylamine (51 mg, 0.260 mniol), HOBT (35 0.260 mmol) and triethylamine (0.073 ml, 0.521 mmol) in dry DMF (3 ml). After 3 d the reaction was diluted with ethyl acetate and was washed with water (lO0mi), and brine, dried (MgSO4) and evaporated in vacuo to give the title compound: 1 H NMR (CDC13) selected signals at 5 1.44 9H, t-Bu), 2.44 3H), 3.09 J 6.3 Hz, 2H, NHCH2 3.34 (br s, I H, NH), 4.30 2H), 4.55 2H), 6.05 J- 7.7 Hz, I1H), 6.79 (br t, NH), 7.23 -7.27 (in, 5H), 7.34 J 7.7 Hz,
IH).
Step B: 3-Benzylsulfonylamino-6-methyl- I -(methylenecarboxamid o-trans -4-aminocyc lohex y meth y D- 2-pV ridin one HCI Gas was bubbled through a solution of 3-benzylsulfonylamino-6-methyl- 1 -(methylenecarboxamido-trans-4-tbutoxycarboiiylaminocyclohexylmethyl)-2-pyridinone (118.6 mg, 0.217 inmol) in ethyl acetate (20 ml) for 5 min at 0 0 C. After 0.5 hour the solution was degassed with argon and evaporated in vacuo The crude product was triturated with ethyl acetate to give the title compound (80. 1 JI- WO 97/01338 PCT/US96/10778 37 mg) as a solid, m.p.>200 0 C: 1H NMR (CD30D) see disappearance of the BOC group; HRMS (FAB) calc'd for C 2 2
H
3 1
N
4 0 4 S 447.2066, found 447.2048.
EXAMPLE IV Preparation of 3-Benzylsulfonylamino-6-methyl- 1-(2-amino-5methylenecarboxamidomethylpyridinvl)-2-pyridinone N NH 2 O' NN 100 N Step A: 3-Benzyloxycarbonylamino-6-methyl-2-pyridinone DPPA (35.6 ml, 165 mmol) was added to a stirred solution of 2-hydroxy-6-methylpyridine-3-carboxylic acid (22.97 g, 150 mmol) and triethylamine (23.0 ml, 165 mmol) in dry dioxane (300 ml) and the resulting solution was heated to reflux. After 16 h more triethylamine (23.0 ml, 165 mmol) and benzyl alcohol (17.1 ml, 150 mmol) were added and the solution was refluxed for a further 24 h. The reaction was concentrated in vacuo to remove most of the volatiles. The residue was partitioned between methylene chloride and brine, acidified to pH 1 with 1 M HCI. The organic layer was washed with sodium hydrogen carbonate solution and brine, dried (MgSO4) and evaporated in vacuo.
The crude product was purified by flash column chromatography (ethyl acetate/hexanes gradient 70-80% ethyl acetate, followed by 59 methanol/chloroform). The resulting solid was recrystallized ftom methanol, to give the title compound (21.15 g, IH NMR (CDC3) 6 2.29 3H, CH3), 5.20 2H, PhCH2), 6.06 J 7.6Hz, pyridinone- 7.32-7.43 5H, Ph), 7.67 (br s, IH, CbzNH), 8.03 (br d, pyridinone-4-H).
I L WO 97/01338 PCTIUS96/10778 -38- Step B: 3-Benzyloxycarbonylamino-6-methyl- I -(t-butylmethvlenecarboxy)-2-pyridinone t-Butylbromoacetate (12.1 ml, 81.98 mmol) was added to a stirred suspension of 3-benzyloxycarbonylamino-6-methyl-2-pyridinone (21.15 g, 81.98 mrno!) and cesium carbonate (26.71 g, 81.98 mmol) in dry DMF (170 ml). After 36 h, the reaction was evaporated in vacuo to a thick paste which was partitioned between ethyl acetate and water. The organic layer was hed with water (3 times) and brine, dried (MgS04) and evaporate, .,cuo. The resulting material was purified by flash column chromatography on silica (20% ethyl acetate/hexanes) to give the title compound (15.00 g, 49%) as a crystalline solid: 1 H NMR (CDCl3) 5 1.47 9 2.25 3 4.75 2 HI), 5.19 2 6.09 J 7.8 Hz), 7.30-7.40 5 7.75 (br s, 1 7.94 (br d, 1
H).
Step C: 3-Amino-6-meo, -l-(t-butyl-methylenecarboxy)-2pyridinone A mixture of 3-benzyloxycarbonylamino-6-methyi-l-(tbutyl-methylenecarboxy)-2-pyridinone (3.16 g, 8.48 mmol) and Pearlman's catalyst (360 mg) in 4:1 ethanol/water (120 mi) was stirred under H2 (balloon) for 16 h. The reaction mixture was filtercd through celite and evaporated in vacuo, azeotroping with ethanol. The crude product was purified by flash column chromatography on silica ethyl acetate/hexanes) to give the title compound (1.58 g, 78%) as a foam: 1 H NMR (CDCl3) 1.46 9H, t-Bu), 2.18(s, 3H, Me), 4.02 (bi s, 2H, NH2), 4.74 2H, CH2), 5.90 J 7.3Hz, 1H, pyridinone 6.47 J 7.3Hz, 1H, pyridinone H-4).
SEpD: 3-Benzylsulfonylamino-6-methyl- I -(t-butyl-methylenecarboxv)-2-pyvridinone Pyridine (6.26 ml) was added to a mixture of 3-amino-6methyl- 1-(t-buty-methylenecarboxy)-2-pyridinone (1.49 g, 6.25 mmol) and benzylsulfonyl chloride (1.31 g, 6.88 mmol) at 0 0 C and as the resulting solution was stirred a thick precipitate formed. More pyridine r I I P' 91-' 1 WO 97/01338 PCT/US96/10778 -39- (3.13 ml) was added and the slurry was stirred for 1 h. The reaction was partitioned between ethyl acetate and water. The cloudy ethyl acetate layer was dried (Na2SO4) and was evaporated in vacuo to give the desired product (1.42 g) as a pale pink solid. More product (0.97 g as a pale yellow solid) was recovered by washing the drying agent and filtration apparatus with methylene chloride. The title compound (2.39 g, 97%) was thus obtained: 1 H NMR (CDCl3) 8 1.51 9H, t-Bu), 2.26 (s, 3H, Me), 4.31 2H, PhCH2), 4.75 2H, NCH2), 6.01 J 7.7Hz, 1H, pyridinone 7.22-7.34 7H, remaining H).
Step E: 3-Benzylsulfonylamino-6-methyl-I-methylenecarboxy-2pyridinone HCI gas was bubbled through a stirred suspension of 3benzylsulfonylamino-6-methyl-1-(t-butyl-methylenecarboxy)-2pyridinone (1.42 g, 3.62 mmol) in ethyl acetate (15 ml) at 0°C until a solution had formed which was saturated with HC1. After 1 h at RT a thick suspension had formed. The mixture was degassed with argon and filtered to give the title compound (0.865 g, 71%) as a solid: IH NMR (CD30D) 5 2.32 3H, Me), 4.43 2H, PhCH2), 4.89 2 H, NCH2), 6.14 J 7.7Hz, 1H, pyridinone 7.28-7.33 6H, remaining H).
Step F: 3-Benzylsulfonylamino-6-methyl-1 methvlenecarboxamidomethylpvridinvl)-2-pyridinone EDC hydrochloride (14.2 mg, 0.178 mmol) was added to a stirred mixture of 3-benzylsulfonylamino-6-methyl- -methylenecarboxy- 2-pyridinone (50.0 mg, 0.149 mmol), 2-amino-4-methylaminopyridine (18.3 mg, 0.149 mmol), HOBT (24.1 mg, 0.178 mmol) and triethylamine (0.050 ml, 0.359 mmol) in dry DMF (1 ml). After 64 h the reaction was diluted with ethyl acetate and was washed with water, saturated sodium hydrogen carbonate solution, water and brine, dried (Na2SO4) and evaporated in vacuo to a solid. The crude product was purified by flash column chromatography on silica (methanol/chloroform gradient, 5-7% methanol),and the resulting material was further purified by preparative WO 97/01338 PCT/US96/10778 HPLC (C18, H20/CH3CN gradient) to give the title compound (14 mg, 21%) as a glass: IH NMR (CD30D) 8 2.33 3H), 3.35 2H), 4.32 2H), 4.44 (s, 2H), 4.81 2H), 6.16 J 7.5Hz, 1H), 6.86 J 8.8Hz, 1H), 7.26- 7.33 6H), 7.78-7.81 2H); MS (FAB) 442 EXAMPLE Preparation of 3-Benzylsulfonylamino-6-methyl- 1-(2-amino-6methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone 0
NH
2 H H N S" SN N N Step A: 3-Benzyloxycarbonylamino-6-methyl-2-pyridinone DPPA (35.6 ml, 165 mmol) was added to a stirred solution of 2-hydroxy-6-methylpyridine-3-carboxylic acid (22.97 g, 165 mmol) and triethylamine (23.0 ml, 165 mmol) in dry dioxane (300 ml) and the resulting solution was heated to reflux. After 16 h more triethylamine (23.0 ml, 165 mmol) and benzyl alcohol (17.1 ml, 150 mmol) were added and the solution was refluxed for a further 24 h. The reaction was concentrated in vacuo to remove most of the volatiles. The residue was partitioned between methylene chloride (500 ml) and brine (500 ml), acidified to pH 1 with 1 M HCI (165 ml). The aqueous layer was extracted with methylene chloride (2 times) and the combined organic layers were washed with sodium hydrogen carbonate solution and brine, dried (Na2SO4) and evaporated in vacuo to a brown solid. This was recrystallized from methanol, to give the title compound (22.70 g. 59%) as a tan solid: IH NMR (CDC13) 8 2.29 3H, CH3), 5.20 2 H, PhCH2), 6.06 J 7.6 Hz, pyridinone-5-H), 7.32-7.43 5 H, Ph), 7.67 (br s, 1 H, CbzNH), 8.03 (br d, pyridinone-4-H).
I I _I WO 97/01338 PCTIUS96/10778 -41 Step B: 3-Benzyloxycarbonylamino-6-methyl- I-(t-butylmethylenecarboxy)-2-pyridinone t-Butylbromoacetate (12.98 ml, 87.89 mmol) was added to a stirred suspension of 3-benzyloxycarbonylamino-6-methyl-2-pyridinone (22.70 g, 87.89 mmol) and cesium carbonate (28.64 g, 87.89 mmol) in dry DMF (175 ml). After 16 h, the reaction was evaporated in vacuo to a thick paste which was partitioned between ethyl acetate and water. The organic layer was washed with water (3 times) and brine, dried (MgSO4) and evaporated in vacuo to a solid. Hexanes (200 ml) was added to this material and the mixture was heated to reflux for 5 min, cooled and filtered, washing with cold hexanes to give the title compound (12.55 g, 38%) as a crystalline solid: 1 H NMR (CDC13) 8 1.47 9 2.25 3 4.75 2 5.19 2 6.09 J 7.8 Hz), 7.30-7.40 5 7.75 (br s, 1 7.94 (br d, 1
H).
Step C: 3-Amino-6-methyl-l -(t-butyl-methylenecarboxy)-2pyridinone A mixture of 3-benzyloxycarbonylamino-6-methyl- butyl-methylenecarboxy)-2-pyridinone (5.59 g, 15.0 mmol) and Pearlman's catalyst (0.56 g) in 4:1 ethanol/water (200 ml) was shaken in a Parr apparatus under H2 (50 psi) for 2 h. The reaction mixture was filtered through celite and evaporated in vacuo, azeotroping with ethanol to give the title compound (3.55 g, 99%) as a solid: 1 H NMR (CDC13) 5 1.46 9 H, t-Bu), 2.18 3 H, Me), 4.02 (br s, 2 H, NH2), 4.74 2 H, CH2), 5.90 J 7.3 Hz, 1 H, pyridinone 6.47 J 7.3 Hz, 1 H, pyridinone H-4).
Step D: 3-Benzylsulfonylamino-6-methyl- -(t-butyl-methylenecarboxy)-2-pyridinone Benzylsulfonyl chloride (3.146 g, 16.5 mmol) was added to a solution of 3-amino-6-methyl- l-(t-butyl-methylenecarboxy)-2pyridinone (3.55 g, 14.9 mmol) in pyridine (30 ml) at 0° C and as the resulting solution was stirred a thick precipitate formed. After I h the 111 L WO 97/01338 PCT/US96/10778 -42 reaction mixture was evaporated in vacuo to a thick paste. This was partitioned between methylene chloride and 10% potassium hydrogen sulfate solution. The organic layer was dried (Na2SO4) and evaporated in vacuo to give the desired product (5.70 g, 97%) as a pale pink solid: 1 H NMR (CDC13) 6 1.51 9 H, t-Bu), 2.26 3 H, Me), 4.31 2 H, PhCH2), 4.75 2 H, NCH2), 6.01 J 7.7 Hz, 1 H, pyridinone 7.22-7.34 7 H, remaining H).
Step E: 3-Benzylsulfonylamino-6-methyl- I-methylenecarboxy- 2-pyridinone HCI gas was bubbled through a stirred suspension of 3benzylsulfonylamino-6-methyl-1 -(t-butyl-methylenecarboxy)-2pyridinone (5.70 g, 14.52 mmol) in ethyl acetate (60 ml) at 0°C until a solution had formed which was saturated with HC1. After 1.5 h at RT a thick suspension had formed. The mixture was degassed with nitrogen and filtered to give the title compound (4.00 g, 82%) as a pale pink solid: IH NMR (CD30D) 8 2.32 3 H, Me), 4.43 2 H, PhCH2), 4.89 2 H, NCH2), 6.14 J 7.7 Hz, 1 H, pyridinone 7.28-7.33 6 H, remaining H).
Step F: 3-Benzylsulfonylamino-6-methyl-1 -(2-amino-6-methyl- 5-methylenecarboxamidomethylpyridinyl)-2-pyridinone DCC (0.61 g, 2.98 mmol) was added to a stirred solution of 3-benzylsulfonylamino-6-methyl- I -methylenecarboxy-2-pyridinone (1.00 g, 2.98 mmol) and 2-t-butoxycarbonylamino-6-methyl-5methylaminopyridine (0.71 g, 2.98 mmol) in methylene chloride (6 ml).
After 3 h the reaction was filtered through celite and evaporated in vacuo to a pale yellow foam. Ethyl acetate (40 ml) was added resulting in a thick precipitate. HCI gas was blown onto the stirred mixture at 0 C causing the bulk of the material to dissolve. Undissolved material was broken up with a spatula and after bubbling HCI through the mixture for min dissolution was complete. Over one hour some precipitate formed. The mixture was degassed with nitrogen and was evaporated in vacuo to a solid. Water (100 ml) was added and the undissolved material 1 9 WO 97/01338 PCT/US96/10778 -43 was removed by filtering through a frit. The solution was washed with methylene chloride (2 times, adding sufficient brine to dissipate the emulsion) and ethyl acetate, then was basified with sodium hydrogen carbonate. The thick precipitate was collected by filtration, washing with water, methanol and ether and was dried at 500 C, 0.5 mm Hg for 64 h to give the title compound (0.83 g, 61%) as a powder: 1H NMR (DMSO) 8 2.23 3 2.24 3 4.13 J 5.3 Hz, 2 H), 4.50 2 4.72 2 5.73 2 6.08 J 8.7 Hz, 1 6.22 J 8.2 Hz, 1 7.11 J 7.5 Hz, 1 7.22 J 8.2 Hz, 1 7.31-7.35 5 8.47 J 5.3 Hz, 1 8.58 1 MS (FAB) 456 Step 2-Amino-5-cyano-6-methylpyridine A mixture of 6-amino-3-bromo-2-methylpyridine (20.0 g, 0.107 mol) and copper cyanide 11.0 g, 0.123 mol) in DMF (25 ml) was heated to reflux for 4 h. The DMF was evaporated in vacuo and the residue was partitioned between ethyl acetate and 10% sodium cyanide solution. The organic layer was washed with 10% sodium cyanide solution and brine, dried (Na2SO4) and evaporated in vacuo to a brown solid. This was dissolved in a minimum amount of ethyl acetate and the product was precipitated by adding hexanes. The mixture was filtered to give the title compound (12.0 g, 85%) as a brown powder: 1H NMR (CDC13) 5 2.56 3 4.97 (br s, 2 6.33 J 8.6 Hz, 1 H), 7.54 J 8.6 Hz, 1 H).
Step 2-t-Butoxycarbonylamino-5-cyano-6-methylpyridine A mixture of 2-amino-5-cyano-6-methylpyridine (10.0 g, 75.1 mmol), (BOC)20 (16.39 g, 75.1 mmol), triethylamine (11.5 ml, 82.6 mmol) and DMAP (92 mg, 7.5 mmol) in methylene chloride (200 ml) was stirred for 3 h. More triethylamine (4.22 ml) and (BOC2)O (1.64 g) were added and after 16 h the reaction was diluted with ethyl acetate and was washed with 1 M AcOH (3 times), dried (Na2SO4) and evaporated in vacuo to give dark brown solid. The crude product was purified by flash column chromatography (10% ethylacetate/hexanes) to give the title compound (14.68 g, 84%) as a white solid: -I I I WO 97/01338 PCT/US96/10778 -44- 1H NMR (CDC13) 5 1.52 9 2.62 3 7.46 (br s, 1 7.80 J 8.8 Hz, 1 7.88 J 8.8 Hz, 1 H).
Step 2-t-Butoxycarbonylamino-5-methylamino-6-methylpyridine A mixture of 2-t-butoxycarbonylamino-5-cyano-6methylpyridine (14.68 g, 62.9 mmol) and 10% Pd/C (1.5 g) in glacial acetic acid (150 ml) was shaken on a Parr apparatus at 60 psi for 88 h.
The reaction was filtered through celite and was evaporated in vacuo. The residue was dissolved in water and the solution was washed with methylene chloride (2 times), then was basified with sodium carbonate and extracted with ethyl acetate (2 times). The combined ethyl acetate layers were dried (Na2SO4) and evaporated in vacuo to a solid. The crude product was recrystallized (ethyl acetate/hexanes) to give the title compound (6.7 g, 1H NMR (CDC13) 6 1.50 9 2.43 3 3.81 2 7.23 (br s, 1 7.57 J 8.3 Hz, 1 7.70 J 8.3 Hz, 1 H).
EXAMPLE VI Preparation of 3-Benzylsulfonylamino- I-(2-amino-6methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone H O H
NH
2 SNN
N
0 2 0 Step A: 3-Nitro-1 -(t-butylmethylenecarboxy)-2-pyridinone t-Butylbromoacetate (1.48 ml, 10 mmol) was added to a stirred suspension of 2-hydroxy-3-nitropyridine (1.40 g, 10 mmol) and cesium carbonate (3.26 g, 10 mmol) in dry DMF (20 ml). After 16 h, the solvent was evaporated in vacuo and the residue was partitioned between water and ethyl acetate. The organic layer was washed with water and brine, dried (Na2SO4) and evaporated in vacuo to a ruby red solid (2.37 WO 97/01338 PCT/US96/10778 1 H NMR (CDC13) 5 1.49 9H), 4.68 2H), 6.34 (dd, J 6.7 and 7.6Hz, 1H), 7.60 (dd, J 2.1 and 6.7Hz, 1H), 8.38 (dd, J 2.1 and 7.6Hz, 1H).
Step B: 3-Nitro- -methylenecarboxy-2-pyridinone HCI gas was bubbled through a stirred suspension of 3-nitro- 1-(t-butylmethylenecarboxy)-2-pyridinone (2.37 g) in ethyl acetate ml) at 0°C until a solution had formed which was saturated with HCI.
After 1 h at RT the mixture was degassed with nitrogen and filtered to give the title compound (1.56 IH NMR (DMSO) shows loss of the tbutyl singlet.
Step C: 3-Nitro-1 -(2-t-butoxycarbonylamino-6-methyl- 5-methylenecarboxamidomethylpyridinyl)-2-pyridinone EDC hydrochloride (249 mg, 1.30 mmol) was added to a stirred mixture of 3-nitro-1-methylenecarboxy-2-pyridinone (198 mg, 1.00 mmol), 2-t-butoxycarbonylamino-5-methylamino-6-methylpyridine (237 mg, 1.00 mmol), HOBT (176 mg, 1.30 mmol) and triethylamine (0.32 ml, 2.30 mmol) in dry DMF (4 ml). After 16 h the solvent was evaporated in vacuo, and the residue was partitioned between methylene chloride and water. The organic layer was dried (Na2SO4) and evaporated in vacuo to a solid. Ethyl acetate was added to the crude product and the resulting mixture was heated to reflux then was cooled and filtered to give the title compound (234 mg) as a solid: IH NMR (DMSO) selected signals at 8 1.45 9H, t-Bu), 2.36 3H, Me), 4.25 J 5.5Hz, 2H, NHCH2), 4.75 2H, CH 2
CO).
Step D: 3-Amino- -(2-t-butoxycarbonylamino-6-methyl- 5-methvlenecarboxamidomethvlpvridinvl)-2-pyridinone A mixture of 3-nitro-I -(2-t-butoxycarbonylamino-6-methyl- 5-methylenecarboxamidomethylpyridinyl)-2-pyridinone (234 mg) and palladium on carbon (60 mg) in ethyl acetate (20 ml) was stirred under hydrogen (balloon) for 4 h. The mixture was filtered through celite and evaporated in vacuo to give the title compound (206 mg) as a solid: WO 97/01338 WO 9701338PCTIUS96/10778 46 1 H NMR (DMS0) 6 1.45 9H, t-Bu), 2.36 3H, Me), 4.22 J= 2H, NHCH2), 4.56 2H, CH2CO), 5.03 2H, NH2), 6.01 J 7.0Hz, I H, pyridinone 6.45 (dd, J 1.6 and 7.1 Hz, I H, pyridinone 6.83 (dd, J 1.6 and 6.8H1z, I H, pyridinone 7.55 2H, pyridinie 8.48 (br t, I H, NHCH 2 9.54 I H, BOCNH).
Step E: 3-Benzylsulfonylamino .1 -(2-t-butoxycarbonylamino-6pyridinone 3-Amino- I -(2-t-butoxycarbonylamino-6-methyl- )-2-pyri dinone (206 mg) was sulfonylated using the procedure of EXAMPLE V, Step D. The crude product was purified by flash column chromatography on silica (methanol/chloroform gradient, 24% methanol) to give a foam which crystallized from ethyl acetate to the title compound (122 mg, 69%): 1 H NMR (CDCI3) selected signals at 5 1.49 9H, t-Bu), 2.39 3H, Me), 4.27 2H), 4.38 J 5.7Hz, 2H, NHCH2), 4.41 2H).
Step F: 3-Benzylsulfonylamino- I -(2-amino-6-methyl-5methylenecarboxamidomethylpyridinyl )-2-pyridinone 3-Benzylsulfonylamino- I -(2-t-butoxycarbonylarnino-6methyl-S -methylenecarboxamidomethylpyridinyl )-2-pyridinone (122 mg) was was deprotected using the procedure of Step B, to give the title compound (93 mg): I H NMR (DMSO) see disappearance of the BOC S64egroup; Anal. (C21H23N504.1.0 HCI. 0.6 H20. 0.4 EtOAc).
EXAMPLE VII Preparation of 3-Benzylsulfonylamino-6-methyl- I -(2-amino-3methy 1-5 -methvlenecarboxamidomethylpyri dinyl )-2-pyridin one 0 N NH 2 02 0 WO 97/01338 PCT/US96/10778 -47- Step A: 2-Amino-5-cvano-3-methylpyridine The title compound was prepared from 6-amino-3-bromo-5methylpyridine using the procedure of EXAMPLE V, Step A' (the crude product was purified by trituration with hot ethyl acetate) as a tan solid: 1 H NMR (CDC13) 5 2.15 3 4.91 (br s, 2 7.46 1 8.25 1
H).
Step B: 2-amino-5-methvlamino-3-methylpyridine A mixture of 2-amino-5-cyano-3-methylpyridine (1.40 g) and 10% Pd/C (0.18 g) in 1:1 ethanol/ M HCI (64 ml) was shaken on a Parr apparatus at 57 psi for 16 h. The reaction was filtered through celite and was evaporated in vacuo, azeotroping with ethanol. The residue was heated to reflux as a suspension in ethanol (15 ml) then the mixture was cooled and filtered to give the title compound (0.68 g): I H NMR (CD30D) 5 2.30 3 4.08 2 7.89 1 7.91 1 H).
Step C: 3-Benzylsulfonylamino-6-methyl- 1 -(2-amino-3-methyl- 5-methylenecarboxamidomethylpyridinyl)-2-pyridinone EDC hydrochloride (69 mg, 0.36 mmol) was added to a stirred mixture of 3-benzylsulfonylamino-6-methyl- I-methylenecarboxy- 2-pyridinone (101 mg, 0.30 mmol), 2-amino-5-methylamino-3methylpyridine (63 mg, 0.30 mmol), HOBT (49 mg, 0.36 mmol) and triethylamine (0.22 ml) in dry DMF (1.2 ml). After 64 h the reaction was evaporated in vacuo then was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium hydrogen carbonate solution and brine, dried (Na2SO4) and evaporated in vacuo to a glass. The crude product was purified by preparative HPLC (C 8, H20/CH3CN/0. 1% TFA gradient) to give the title compound (97 mg) as a crystalline solid, m.p. 226-229' C: 1 H NMR (DMSO) 8 2.15 3 2.26 3 4.20 J 5.5 Hz, 2 H), 4.51 2 4.74 2 6.11 J 7.5 Hz, 1 H) 7.13 J 7.5 Hz, 1 7.29-7.31 5 7.71-7.73 4 H),8.48 1 8.76 (br t, 1 H); WO 97/01338 PCTUS96/10778 48 HRMS (FAB) calc'd for C22H26N504S 456.1706, found 456.1694.
EXAMPLE VIII Preparation of 3-Benzyloxycarbonylamino-6-methyl- I -(4-methylenecarboxarnidomethyl-1-amidinopiperidinvl)-2-pyridinone
NH
H H N NH 2 0"0 YNN
N
ONN
0 0 HCI gas was bubbled through a stirred suspension of 3benzloxycarbonylamino-6-methyl-1 -(4-methylenecarboxamidomethyl- 1t-butoxycarbonylpiperidinyl)-2-pyridinone (0.12 g) in ethyl acetate (5 mi) at O0 C until a solution had formed which was saturated with HCL. After I h at RT a thick suspension had formed. The mixture was degassed with argon and evaporated in vacuo to give 3-benzloxycarbonylamino-6methyl- I -(4-methylenecarboxamidomethylpiperidinyl)-2-pyridinone hydrochloride as a solid (0.10 Aminoiminomethanesulfonic acid (0.040 triethylamine (83.6 pLl) and DMIF (1 ml) were added to this material and the mixture was stirred at RT for 48 h. The reaction was evaporated in vaCUO and the crude product was purified by preparative HPLC (C18, 0.1% TFA/H20,CH3CN gradient) to give the title compound as a white solid, m.p. >200oC: 1H NMR (CD30D) 6 1.24 (m, 2 1.83 3H), 2.33 3H), 3.04 2H), 3.16 2H), 3.87 (br d, J 13.7 Hz, 2H), 4.82 2H), 5.19 2H), 6.25 J 7.5 Hz, 1H), 7.28- 7.32 6H), 8.34 (br m, 1H); MS (FAB) 455 EXAMPLE IX Preparation of 3-(3-Phenylpropionamido)-6-methyl-1 -(4-methylene carboxamidnethyl- I -amidinopiperidinvll-2-pyridinone I- l-els--' WO 97/01338 WO 9701338PCT/US96/1 0778 49
NH
H H NH 2
INH
0 0 Step 3-(3-Phenylpropionamido)-6-methyl- 1 -(4-methylenecarboxamidomethyl- 1 -t-butoxycarbonylpiperidinyl)-2pyridinone Hydrocinnamoyl chloride (56 mg, 0.3 29 mmol) was added to a stirred solution of 3-amino-6-methyl- 1 -(4-methylenecarboxamidomethyl- I -t-butoxycarboniylpiperidinyl)-2-pyridinone (83 mg, 0.220 mmol) and triethylamine (92 tl, 0.660 mmol) in methylene chloride (1 ml). After 16 h the reaction directly purified by flash column chromatography on silica (eluting with 80% ethyl acetate/hexanes) to give the title compound: I 1 H NMR (CDCI3) selected signals at 6 1. 10 (in, 2 1 .44 9H), 1.63 (in, 3H), 2.44 3H), 2.66 (mn, 2H), 2.71 J 7.8 Hz, 2H), 3.05 J =7.8 Hz, 2H), 3.12 (in, 2H), 4.11 (br in, 2 4.71 2H), 6.17 J 7.6 Hz, I1H), 7.20-7.3 3 (in, 5 8. 35 (br in, I1H).
Step B: 3-(3 -Phenyl prop ionani do)- 6-methyl I (4-methylenecarboxamidoinethyl- 1 -ami dinopi~e ridiny I)-2-pyrid inone 3-(3-Phenylpropionamido)-6-inethyl- I -(4-methylenecarboxamidomethyl -1-t-butoxycarbonylpiperidinyl )-2-pyridinone (0.058g) was deprotected with HCl and then amidinylated as described in EXAMPLE VIfI to give the title compound as a white solid: I H NMR (CD3OD) 6 1.24 (in, 2 1.83 (in, 2H), 2.33 3H), 2.73 3H), 2.97 3H), 3.04 (mn, 1H), 3.16 (in, 2H), 3.87 (br d, J 13.7 Hz, 2H), 4.80 (s, 2H), 6.25 J 7.7 Hz, 1 7.16-7.27 (in, 6H), 8. 18 J 7.7 Hz, IJH), 8.30 (br m, I MS (FAB) 453 WO 97/01338 WO 9701338PCTJUS96/1 0778 50 EXAMPLE X Preparation of 3-(3 ,3-Diphenylpropionamido)-6-methyl- 1 methylenecarboxamidomethyl-1 -arnidinopiperidinyl)-2-pvridinone
NH
H 0H N 11NH 2 -YN N _r 0 0 Step A: 3-(3,3-Diphenylpropionamido)-6-methyl- I -4-methylenecarboxamidomethyl- I -t-butoxycarbonylpiperidinyl)-2pvridin one EDC hydrochloride (75 mg, 0.393 mmol) was added to a stirred mixture of 3-amino-6-methyl-lI-(4-methylenecarboxamidomethyl- I -t-butoxycarbony lp iperi diny1) -2-pyri dino le (99 mg, 0.262 mr-nol), 3,3-diphenyipropionic acid (71 mg, 0.3 14 mmol), HOBT (53 mg, 0.393 mmol) and diisopropylethylamine 14 ml, 0.786 mmol) in dry DMF (I ml). Aftter 64 h the reaction was diluted with ethyl acetate and was washed with water, dried {MgSO4) jnd evaporated in vacuo. The crude product was purified by flash column chromatography on silica (eluting with 60% ethyl acetate/hexanes') to give the title compound (62 mg): I1 NMR (CDCI3) selected signals at 6 1.45 9H), 3.14 2H), 4.67 (br m, 3H), 7.26 (in, I OH).
StepV B: 3-(3,3-Diphenylpropionamido)-6-rnethyl- I -(4-methylenecarboxamidomethyl- I -ami din opiperi diny 2-12yridi none 3-(3,3-Diphenylpropionamido)-6-methyl- 1 -(4-methylenecarboxamidomethyl -1 -t-butoxycarbonylpiperidinyl )-2-pyridinone (0.062g) was deprotected with HCI and then amidinylated as described in EXAMPLE VIII to give the title compound as a white solid: 1 NMR (CD3OD) 5 1.23 (in, 2 1.83 (in, 2H), 2.30 3H), 3.06 1H), 3.16 WO 97/01338 WO 9701338PCT/US96/10778 -51 (in, 2H), 3.87 (br d, J 13.7Hz, 2H), 4.60 I 4.78 2H), 6.18 J 7.7 Hz, I 7.13-7.30 (mn, 6H), 8.06 J 7.7 Hz, I 8.29 (br rn, I MS (FAB) 529 EXAMPLE X1
NH
H 0HN J NH N N-'"YN 02 1K Preparation of 3-p-Toluenesulfonylamino-6-methyl- I -(4-inethylenecarboxamidomethyl- I -amidinopiperi din y )-2-pyfidi none Step A: 3-p-Toluenesulfonylamino-6-methyl- 1 methylenecarboxamidomethyl-I1 -tbutoxycarbonylpiperidinyvb-2-pyridinone p-Toluenesulfonyl chloride (22 mg, 0. 116 rmol) was added to a stirred solution of 3-amino-6-methyl- I -(4-methylenecarboxamidoinethyl -1-t-butoxycar-bonylp, 4 ri dinyl )-2-pyridinoric mg, 0. 106 rnm-ol) in pyridine (0.5 ml). After 2 h the reaction mixture was partitioned between 10% citric acid solution and ethyl acetate. The organic layer was dried (MgSO4), filtered and concentrated in vaUCUO.
The resulting material was purified by flash column chromatography on silica (eluting with a methanol/chloroform gradient, 2-5% methanol) to give the title compound (27 mg). IH NMR (CDCI3) selected signals at 6 1.45 9H), 2.39 3H), 2.41 3H), 6.06 J 7.7 Hz, I1H), 7.24 (in, 2H), 7.46 J 7.7 Hz, I1H), 7.7 3 (mn, 2H).
Step B: 3-p-Tfoluenesulfonylamino-6-inethyl- I -(4-inethylenecarboxainidomethyl-1 -amidinopiperi din y )-2-pyrid inone 3-p-Toluenesulfonylamino-6-methyl- 1 methylenecarboxamidoinethyl- I -t-butoxycarbonyl-piperidiniyi WO 97/01338 WO 9701338PCTIUS96/1 0778 52 pyridinone (0.027g) was deprotected with HCI and then amidinylated as described in EXAMPLE VJTJ to give the title compound as a white solid: I H NMR (CD3 OD) 8 1. 23 (in, 2 1. 81 (in, 2H), 2.27 3 2.3 8 (s, 3H), 3.06 (mn, I 3.13 (in, 2H), 3.86 (br d, J 13.9 Hz, 2H), 4.67 (s, 2H), 6.15 J 7.7 Hz, I1H), 7.29 (in, 2H), 7.43 J 7.7 Hz, I H), 7.71 (in, 2H), 8.23 (br m, I MS (FAB) 475 EXAM-PLE XII Preparation of 3-p-Toluenesulfonylamino-6-methy -I1 -(methylenecarbox aiido-trans -4-aminocycl ohex ylmethv )D-2-p yri dinone 0
NH
2 C_ SN
N
02 0 Step A- 3-p-Toluenesulfonylainino-6-methyl- I -(methylenecarboxamido-trans-4-t-butoxycarbonylaminocyclohexylmethyl )-2-pyridinone 3 -Amino -6-methyl -I (methylenecarboxamido-trans -4t-butox ycarbonvlamiriocyclohexylmethyl )-2-pyri din one (20 ing, 0.051 inmol) was sulfonylated using the procedure of EXAMPLE X1, Step A to gnve the title compound (18 mg): IH NMR (CDCI3) selected signals at 1.44 9H), 2.39 6H), 6.07 J 7.6 Hz, 1H), 7.24 (mn, 2H), 7.45 (d, J 7.6 Hz, I1H), 7.7 3 (mn, 2H).
Step B: 3-p-Toluenesulfonylamino-6-methyl- I -(methy lenecarboxamido-trans-4-aminocyclohexvlmethyl)-2-pvridinone 3-p-Toluenesulfonylainino-6-methyl- 1 -(inethylenecarboxainido-trans -4-t-butoxycarbonylamninocyclohexyli-ethyl)-2-pyridinone (18 mg) was dissolved in ethyl acetate saturated with HCI gas (5 ml).
After 45 min. the solution was degassed with argon and evaporated in vacuo to a yellow solid. The crude product was purified by preparative WO 97/01338 WO 9701338PCTIUS96/10778 53 HPLC (C is, 0. 1% TFA/H20,CH3CN gradient) to give the title compound as a solid: I H NMR (CD3OD) d 1.06 (in, 1.21 (in, 2H).
1 .35 (in, 2H), 1.87 (in, 2H), 2.04 (mn, 2H), 2.26 2.38 3.06 (mn, 4H), 4.67 2H), 6.15 J 7.1 Hz, I 7.29 (in, 2H), 7.43 J= 7.1 Hz, I1H), 7.71 (mn, 2H), 8. 19 (in, I MIS (FAB) 447 EXAMPLE XI Preparation of 3-Phenylacetamido-6-methyl -I -(2-amino-S .aethyvlenecarboxamidomethylpyridinyl )-2-pyri dinone
NH
2 H 0H 'N N -I N Step A: 3-Phenylacetamido-6-methyl- I -(2-t-butoxycarbonylam mno- )-2-pyridinone Phenylacetyl chloride (18 mg, 0. 114 mm-ol) was added to a stirred solution of 3 -ainino-6-methyl-l1-(2-t-butoxycarbonylainino-5 methylenecarboxamidomethylpyridinyl )-2-pyridinone (40 mg, 0. 103 mmol) in pyridine (I ml). After 1 h the reaction mixture was partitioned between methylene chloride and water. The organic layer was washed with water and brine, dried (MgSO4), filtered and concentrated in vacuo.
The resulting material was purified by flash column chromatography on silica (70% ethyl acetate/hexane) to give the title compound (28 mg): I H NMR (CDCI3) selected signals at 8 1.52 2.40 3.73 (s, 2H4), 4.33 (in, 4.69 2H4), 6.14 J 7.7 Hz, IJH), 7.26-7.38 (br m, Step B: Phenylacetamido-6-inethyl-1- (2-a-mino-S inethylenecarboxamidomethyl pyri dinyl )-2-pyridin one The title compound was prepared from phenylacetamido-6methyl-i -(2-t-butoxycarbonylamino-5-methy lenecarboxainido- WO 97/01338 WO 9701338PCT[US96/10778 54 methylpyridinyl>-2-pyridinone (0.028 g) using the procedure of EXAMPLE XII, Step B as a white solid (4.2 mg). IH NMR (CD3OD) 8 2.31 3H), 3.75 2H), 4.29 2H), 4.73 2H), 6.23 J 7.5 Hz, I 6.97 J 8. 9 Hz, I1H), 7.27-7.34 (in, 6H), 7.7 6-7.86 (in, 2H), 8. 18 (in, I MS (FAB) 406 EXAMPLE XIV Preparation of 1-Napthylsuffonyl)amino-6-methyl- 1 methylenecarboxamidomethylpvyridinyl )-2-pvyridinone N NH 2 H 0H N S' N ,XN 02 The title compund was prepared from 1 -napthylsulfonyl chloride (64 mg, 0.283 inmol) and 3-amino-6-methyl-1I-(2-tbutox ycarbonyl amino -5 -methy lenecarbo xaiidomethyl py rid in y l)-2 pyridinone 100 g, 0.258 inmol) using the procedure of EXAMPLE XIfl, as a white solid, m.p. >200'C: lH NMR (CD3OD)562.22 3H), 4.24 2H), 4.62 2H), 6. 10 J 7.6 Hz, I1H), 6.96 J 9.3 Hz, 1H), 7.32 J 9.3 Hz, 1H), 7.5 1-7.61 (mn, 3H), 7.73 lH), 7.84 (dd, J 2.2 and 9.2 Hz, I 7.96 (in, I 8. 12 J 8.3 Hz, I1H), 8.24 (mn, 1H), 8.68 (mn, 2H); MS (FAB) 478 EXAMPLE XV Preparation of 3-(2-Napthylsulfonyl)amino-6-inethyl- 1 rnethylenecarboxainidoinethylpyridiflyl )-2-pyridinone WO 97/01338 WO 9701338PCTIUS96/10778 55 H 0H 'N NH SN N N ~2 1 The title compound was prepared from 3-amino-6-methyl-lI- (2-t-butoxycarbonylamino-5-methylenecarboxamidomethylpyridinyl)-2pyridinone 100 g, 0.258 mmol) and 2-napthylsulfonyl chloride (64 mg, 0.283 mmol) using the procedure of EXAMPLE XIII as a white solid, m.p. 188-190'C: I H NMR (CD3OD) 862.25 3H), 4.21 2H), 4.65 (s, 2H), 6.17 J 7.6 Hz, I1H), 6.91 J 9. 0 Hz, I 7.10-7.23 4H), 7.52-7.99 (in, 9H), 8.41 (in, I1H); MS (FAB) 478 EXAMPLE XVI Preparation of 3-(4-Trifluoromethylbenzylsulfonyl)amnino-6-methyl- 1 diri l-2-pvri dinone N NH 2 H 0
H
N N 020
F
3 C l2
I
Step A: 4-Trifluoromethylbenzylsulfonvl chloride A mixture of 4-trifluoromethylbenzyl chloride (1.0 g, 5.14 mmol) and sodium thiosulfate (0.8 13 g, 5.14 inmol) in methanol (1.5 ml) and H20 (1.5 ml) was heated to reflux for 3 h. The mixture was cooled to 0 0 C and glacial acetic acid (1.5 ml) and ice were added. Chlorine gas was bubbled through the resulting suspension for 1 h, periodically adding ice to maintain an ice/liquid mixture. After an additional hour, the reaction was extracted with ether and the ether layer was washed with sodium bisulfite and water, dried (MgSO4), filtered, and evaporated in vacuo to give the title compound as a white solid (0.932 a).
WO 97/01338 WO 9701338PCTIUS96/10778 56 Step B: 3-(4-Trifluoromethylbenzylsulfonyl )amino-6-methyl I -(2-t-butoxycarbonylamino-6-methyl-5methylenecarboxamidomethvlpvyri dinyl)-2-pyri din one The title compound was prepared from 3 -amino-6-methyl-lI (2-t-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone 100 g, 0.249 mmnol) and 4trifluoromethylbenzylsulfonyl chloride (64 mg, 0.249 mmol) using the procedure of EXAMPLE XIfl, as a white solid (60 mg), m.p. >200-C: IH NMIR (CD3OD) 6 2.30 3 2.51 3 4.32 J 5.6 Hz, 2 H), 4.55 2 4.79 2 6. 10 J 7.6 Hz, I 6. 81 J 9.3 Hz, 1 7.31 J =7.8 Hz, 1 7.51 J 8.3 Hz, benzene aromatic HA), 7.58 J =8.3 Hz, benzene aromatic HB), 7.88 J 9.0 Hz, I1H), 8.75 (in, I1H); MS (FAB) 524 EXAMPLE XVII Preparation of 3-(2-Napthylsulfonyl)amino-6-methyl- I -(2-amino-6methyl-S -methylenecarboxamidomethylpvyridinyl -pyridinone H 0 HNNH 2 N N 02 K- 0 The title compound was prepared from 3-amino-6-methyl-lI- (2 -t-bu tox ycarbonylIamino -6-methyl1-5 -methy lenecarbox am ido methylpyridinyl)-2-pyridinone 100 g, 0.249 mmol) and 2napthylsulfonyl chloride (56 mng, 0.249 mmol) using the procedure of EXAMPLE XIflI, as a white solid (72 mg), m.p. >200'C: I H NMR (CD3OD) 6 2.23 3H), 2.44 3 4.20 J 5.9 Hz, 2 4.63 (s, 2 6.16 J 8.1 Hz, 1 6.75 J 9.3 Hz, 1 7.10-7.23 (in, 2H), 7.5 1-8.00 (in, 7H), 8.41 I 8.5 9 (in, I MS (FAB) 492 WO 97/01338 WO 9701338PCT[US96/10778 57 EXAMPLE XVIfl Preparation of 3-(4-Fluorobenzylsulfonyl )amino-6-methyl- 1 -(2-amino-6- )-2-pyridiinne N NH 2 H 0HI F' 5 N N N D Step A: The title compound was prepared from 4- P )oromethylbenzyl chloride (1.0 g) using the procedure of EXAMPLE X- V'I, Step A, as a heavy oil.
Step B: The title compound was prepared from 3-amino-6-methyl- I- (2 butox ycarbony Iamino -6 -methyl1-5 -methylIenecarboxami domethyI pyridirnyl)-2-pyridinone 100 g, 0.249 mmnol) and 4-fluoromethylbenzylsulfonyl chloride (52 mg, 0.246 mmol) using the procedure of EXAMPLE XIII, as a white solid: IlH NMR (CD3OD) 6 2.33 3 H), 2.51 3 4.32 J 5.9 Hz, 2 4.43 2 4.80 2 6.16 J 7.3 Hz, I 6.80 J 8.8 Hz, I 6.97 (in, 2 7.0 1-7.34 (in, 3H), 7.88 J 9.0 Hz IH), 8.75 (mn, I MIS (FAB) 474 EXAMPLE XIX Preparation of -3 -(2-Phenethyiamino)-6-methyl I -(2-ainino-6methyl-S -methylenecarboxamidomethylpvyridinyl )-2-pyridinone N NH 2 0 The title compound was prepared from 3 -amino-6-inethyl 1 (2-t-butoxycarbonylamino-6-inethy 1-5 -methylenecarboxa-midoinethylI.
I
WO 97/01338 WO 9701338PCTIUS96/10778 58 pyridinyl)-2-pyr-idinone (0.060 g, 0. 15 mmol) and phenylacetaldehyde (19.5 [tl, 0. 165 rnmol) using the procedure of EXAMPLE 1LU, as a pale yellow solid, m.p. >200"C: I H NMR (CD3OD) 5 2.25 3H), 2.50 3 2.92 (in, 2H), 3.30 (in, 2H), 4.28 J 5.6 Hz, 2 4.76 2 H), 6.16 J 7.3 Hz, 1 6.41 J 7.3 Hz, 1 6.81 J 9.3 Hz, IH), 7.18-7.28 (in, 4H), 7.85 J 9.3 Hz, 1H), 8.65 (in, I MIS (FAB) 406 EXAMPLE XX Preparation of 3 -Benzylsulfonylamino-6-methyl -1-(2-amino-4me thy 1-5-methy lenecarbo xami do methy lpyri dinl y 2-pyri din one 0 "N NH 2 N N The title compound was prepared from 2-amino-5-bromo-4methylpyridine using the procedure of EXAMPLE VIl, as a solid, m.p.
>200 0 C: I 1 H NMR (CD3OD) selected signals at 5 2.35 3H), 2.41 (s, 3H), 4.34 2H), 4.44 2H), 4.81 2H), 6.18 J 7.5 Hz, I H), 6.81 I 7.24 7.30 (in, 5H), 7.32 J 7.7 Hz, I1H), 7.76 11H); HRMS (FAB) calc t d for C22H26N5O4S 456.1705, found 456.1706.
EXAMPLE XXI Preparation of 3-Benzylsulfonylamino-6-methyl- 1 -(2-amino-4,6- )-2-pyridinone WO 97/01338 WO 9701338PCTIUS96/10778 59 0N
NH
2 H H N N 02 The title compound was prepared from 3benzylIsulIfonylIamino -6-methyl -1 -methylenecarboxy-2-pyridinone (100 mng, 0.297 mmol) anid 2-t-butoxycarbonylamino-4,6-dimethyl-5methylaminopyridine [which was prepared from 2-amino-5-c yano-4,6dimethy lpyri dine using the procedure of EXAMPLE V, Steps B' and C' mg, 0.297 mmol)] using the procedure of EXAMPLE V, Step F, as a solid: I H NMR (DMSO) selected signals at 6 2.22 3 2.35 3 H), 4.21 2 4.50 2 4.67 2 6.09 1 6.63 I 7.09 1 7.11-7.32 (in, 5 7.54 (br s, NIB), 8.53 (br s, HRMS (FAB) calc'd for C23H28N504S 470.1862, found 470.1859.
EXAMPLE XXfl Preparation of 3-(4-Chlorobenzylsulfonylaminio)-6-methyl- I -(2-amino-6meth yl1-5 -methylenecarboxamidomethy lpyri dini y -2 -pyvidinone H H N
NH
2 CIS N N N.
Step A: 3-(4-Chloro-benzylsulfonylainino)-6-methyl- 1I(-btl methylenecarboxy)-2-pyridinone The title compound was prepared from 4chlorobenzylsulfonyl chloride (336 mng, 1.49 inmol) and 3-amino-6methyl- I -(2-t-butoxycarbonylamino-6-methyI-S meth ylenecarbo xamido methylpyri dinyl 1)-2 -pyri din one (400 mg, 0.996 rnmol) using the procedure of EXAMPLE XII, Step A, as a pale pink solid (from ethyl acetate): 1 H NMR (CDCI3) selected signals at a 1.50 (s, WO 97/01338 PCT/US96/10778 9 H, t-Bu), 2.40 3 2.46 3H), 4.16 21-H), 4.37 J 5.7 Hz, 2H), 4.45 2H), 6.09 J 7.9 Hz, 1 H, pyridinone 7.07 7.15 4 7.11 J 7.5 Hz, 1H, pyridinone 7.51 J 8.2 Hz, 1H), 7.64 J 8.2 Hz, 1H), 8.22 (br s, 1H).
Step B: 3-(4-Chloro-benzylsulfonylamino)-6-methyl- I -(2-amino-6methyl-5-methylenecarboxamidomethylpyridinyl)-2pyridinone HCI gas was bubbled through a stirred suspension of 3-(4chloro-benzylsulfonylamino)-6-methyl -1 -(t-butyl-methylenecarboxy)-2pyridinone (325 mg, 14.52 mmol) in ethyl acetate (10 mi) at 0 0 C until a solution had formed which was saturated with HCI. After 1.5 ha thick suspension had formed. The mixture was degassed with argon and filtered to give the title compound (202 mg) as a solid. m.p. >200 0 C: 1
H
NMR (DMSO) see disappearance of the BOC group; HRMS (FAB) calc'd for C22H25N504SC1 490.1316, found 490.1300.
EXAMPLE XXIf Preparation of 3-Benzylsulfonylamino-6-trifluoromethyl-I -(2-amino-6methyl-5-methvlenecarboxamidomethylpyvridinl )-2-pvridinone N
NH
2 H H S' N
N
SF N Step A: 3-Nitro-6-trifluoromethl-2-pyridinone Butyl-2-trifluoroacetylvinylether (13.79 g, 70.29 mmol) and nitroacetamide (6.65 g, 63.90 mmol) were added to a stirred solution of sodium ethoxide (4.35 g, 63.90 mmol) in ethanol (320 ml). After heating the reaction at reflux for 24 h the residue was taken up in ethyl acetate and washed with IM HCI (two times), dried (Na2SO4), and evaporated in vacuo. The crude product was purified by flash column chromatography on silica (eluting with 20% ethyl acetate/2% acetic dl I I L~ I L I WO 97/01338 PCTIUS96/10778 -61 acid/hexane) to give the title compound (5.73 IH NMR selected signals at 8 7.35 J 8.1 Hz, 1H), 8.49 J 8.1 Hz, 1H).
Step B: 3-Nitro-6-trifluoromethyl- 1-allyl-2-pyridinone A solution of allyl acetate (13.5 ml, 125 mmol) in THF (8 ml), was evacuated and purged with argon (3 times). Palladium acetate (122 mg, 0.50 mmol) and triphenylphosphine (525 mg, 2.0 mmol) were added as solutions in tetrahydrofuran (1.5 ml each), followed by 3-nitro- 6-trifluoromethyl-2-pyridinone (2.6 g, 12.5 mmoi) in THF (2 ml). The reaction was heated to reflux for 64 h, and more allyl acetate (13.5 ml.
125 mmol), triphenylphosphine (525 mg, 2.0 mmol), palladium acetate (122 mg, 0.5 mmol), and tetrahydrofuran (13 ml) were added. After a further 24 h and 48 h at reflux addditional allyl acetate (13.5 ml, 125 mmol), palladium acetate (122 mg, 0.5 mmol), and triphenylphosphine (525 mg, 2.0 mmol) were added and the reaction was heated to reflux for a further 24 h. The reaction was cooled and evaported in vacuo to a gum which was purified by flash column chromatography on silica (15% ethyl acetate/hexane) to give the product contaminated with unreacted 3-nitro- 6-trifluoromethyl-2-pyridinone. This material was diluted with ethyl acetate and washed with water adjusted to pH 12 with sodium carbonate, dried (Na2SO4), and evaporated in vacuo to give the title compound (1.05 1H NMR (CDC13) selected signals at 5 4.80 J 5.8 Hz, 2H), 5.28 5.33 2H), 5.86 5.96 1H), 6.80 J 7.9 Hz, 1H), 8.22 J 7.9 Hz, 1H).
Step C: 3-Amino-6-trifluoromethyl- 1 -allvl-2-pyridinone A solution of tin(II) chloride (924 mg, 4.09 mmol) in concentrated HCI (2.5 ml) was added dropwise to a stirred solution of 3nitro-6-trifluoromethyl-1 -allyl-2-pyridinone (127 mg, 0.512 mmol) in THF (6.5 ml) at -10° C. After I h at 0° C, the reaction was poured into a mixture of 50% sodium hydroxide and ice. The product was extracted into ethyl acetate, dried (Na2SO4), and evaporated in vacuo to give the title compound (106 mg): 1H NMR (CDC13) selected signals at 8 4.63 r I I I a~p III WO 97/01338 PCT/US96/10778 -62- (br s, 2H, NH2), 4.74 J 5.4 Hz, 2H), 5.11 5.23 2H), 5.86 5.99 1H), 6.42 J 7.7 Hz, 1H), 6.64 J 7.7 Hz, 1H).
Step D: 3-Benzylsulfonylamino-6-trifluoromethyl- 1-allyl-2pyridinone Benzylsulfonyl chloride (103 mg, 0.542 mmol) was added to a stirred solution of 3-amino-6-trifluoromethyl- -allyl-2-pyridinone (106.5 mg, 0.488 mmol) in pyridine (1 ml) at 0° C. After 1 h the reaction was evaporated in vacuo and the residue was paritioned between methylene chloride and 10% potassium hydrogen sulfate solution, dried (Na2SO4), and evaporated in vacuo to give the title compound (175.8 mg): 1 H NMR (CDCI3) selected signals at 6 4.42 2H), 4.74 J Hz, 2H), 5.16 5.31 2H), 5.86 5.96 1H), 6.55 J 7.7 Hz, 1H), 7.11 J 7.9 Hz, IH), 7.27 7.33 5H), 7.70 (br s, 1H, NH).
Step E: 3-Benzylsulfonylamino-6-trifluoromethyl-2-pyridinone-1 methylenecarboxaldehvde Sodium periodate (414 mg, 1.935 mmol) and ruthenium (III) chloride hydrate (2.15 mg, 0.0104 mmol) were added a mixture of 3benylsulfcptylamino-6-trifluoromethyl-1 -allyl-2-pyridinone (176 mg, 0.472 mmol) in carbon tetrachloride (0.94 ml), water (1.41 ml), and acetonitrile (0.94 ml). After 3 h, the reaction was diluted with methylene chloride, washed with water, dried (Na2SO4), and evaporated in vacuo to give the title compound (137.5 mg): 1 H NMR (DMSO) selected signals at 6 4.65 2H), 4.99 2H), 6.80 J 8.1 Hz, 1H), 7.16 J 7.8 Hz, IH), 7.28-7.35 5H), 9.36 1H, NH), 9.63 IH, CHO).
Step F: 3-Benzylsulfonylamino-6-trifluoromethyl- methylenecarboxy-2-pyridinone Jones Reagent (2.7M) was added dropwise to a stirred solution of 3-benzylsulfonylamino-6-trifluoromethyl-2-pyridinone-1methylenecarboxaldehyde (89 mg) in acetone (5 ml) at 0°C until the color remained orange. Ethanol was added until the reaction changed to a green color and the mixture was diluted with ethyl acetate and washed
~,I
WO 97/01338 PCTIUS96/10778 63with water, dried (Na2SO4), and evaporated in vacuo to give the title compound (84 mg): IH NMR iDMSO) shows the disappearance of the aldehyde peak.
Step G: 3-Benzylsulfonylamino-6-trifluoromethyl-1 -(2-amino-6methyl-5-methylenecarboxamidomethylpyridinyl)-2pyridinone DCC (31 mg, 0.151 mmol) was added to a stirred solution of 3-benzylsulfonylamino-6-trifluoromethyl- 1 -methylenecarboxy-2pyridinone (59 mg, 0.151 mmol) and 2-t-butoxycarbonylamino-6-methyl- (39 mg, 0.166 mmol) in methylene chloride (0.55 ml). After 3 h the reaction was filtered through a cotton wool plug and evaporated in vacuo. The residue was taken up in methanol, filtered and purified by preparative HPLC (Cl8, 0.1% TFA,H20/CH3CN gradient) followed by flash column chromatography on silica (3:1 hexane/acetone then 50% ethyl acetate/I acetic acid/hexane) to give the coupled product (53 mg). Ethyl acetate (5 mi) was added and HCI gas was bubbled through the stirred mixture at 0 0 C until the reaction was a saturated solution. After 3 h at RT, the reaction was degassed with argon and filtered to give the title compound (38 mg), m.p. 161-168OC: 1H NMR (DMSO) selected signals at 6 2.42 3H), 4.17 J 5.5 Hz, 2H), 4.66 J 6.6 Hz, 2H), 6.79 J 7.9 Hz, 2H), 7.16 J 8.1 Hz, IH), 7.29 7.33 5H), 7.61 (br s, 2H, NH2), 7.74 J 9.0 Hz, 1H), 8.71 1H, NH), 9.26 1H, NJH); HRMS (FAB) calc'd for C22H2 3
N
5 04F 3 S 510.1423, found 510.1421.
EXAMPLE XXIV Preparation of 3-(4-Chlorobenzylsulfonylamino)-6-trifluoromethyl- 1-(2amino-6-methl-5-methlenecarboxamidomethylpyridinvl )-2-pridinone WO 97/01338 WO 9701338PCTJUS96/1 0778 64 o N NH 2 H H NN -YN,,U C11 I ,C F 3 The title compound was prepared 4-chlorobenzylsulfonyl chloride using the procedures of EXAMPLE XXIII, Steps D-G, as a white solid, m.p. 170-198 0 C: I H NMR (CD3OD) selected signals at 2.51 3H), 4.32 2H), 4.54 2H), 4.80 2H), 6.75 J 8.1 Hz, I 6. 81 J 9.0 Hz, 1 7.24 7.44 (in, 5H), 7.86 J 9.0 Hz, I 8.70 I H, HRMS (FAB) calc'd for C22H22N504SC1F3 544.1033, found 544.1029.
EXAMPLE XXV Preparation of 3-Benzylsulfonylamino-6-methyl-l1-14-methylenecarboxamidomethyl-l1-(hydroxyamino)iminomethylpiperidiinvll-2-pyfidinone H 0H N NHOH N N 02 Step A: 3- Benzy Isulfonylamino-6-methyl- I -(4-methylenecarboxamidomethy lpiperi dinyl )-2-pyfi din one The title compound was prepared from 3-benzylsulfonylamino-6-methyl-1I-methylenecarboxy-2-pyridinone (0.500 g, 1.49 mmol) and 4-aminomethyl- I -t-buto, ,ycarbonylpiperidiine (0.3 18 g, 1.49 mmol) using the procedure of EXAMPLE V, Step F, as a foam (0.764 I H NMR (CD3OD) 5 1.40 (in, 2 1.80 (in, 3H), 2.33 3H), 2.97 (in, 2H), 3.22 (in, 2H), 3.42 (br d, J 15.1 Hz, 2H), 4.45 2H), 4.79 2 6.15 J 7.6 Hz, I1H), 7.29-7.34 (in, 6H), 8.37 (br mn, I1H).
WO 97/01338 PCT/US96/10778 65 Step B: 3-Benzylsulfonylamino-6-methyl- I -(4-methylenecarboxamidomethyl- 1 -cyanopiperidinyl-2-pridinone To a stirred solution of 3-benzylsulfonylamino-6-methyl-1- (4-methylenecarboxamidomethylpiperidinyl)-2-pyridinone (0.100 g, 0.231 mmol) and sodium acetate (94.7 mg, 1.16 mmol) in methanol (2 mi) was added cyanogen bromide (48.9 mg, 0.462 mmol). The resulting heterogeneous mixture was stirred at RT for 3.5 h and concentrated in vacuo. The crude product was purified by flash column chromatography on silica (methanol/chloroform gradient, 2-10% methanol) to give the title compound (87 mg): 1 H NMR (CD30D) shows a downfield shift of the piperidine H's compared to the starting material.
Step C: 3-Benzylsulfonylamino-6-methyl- I -[4-methylenecarboxamidomethyl-1-(hydroxyamino)iminomethylpiperidinyl pvridinone To a stirred solution of hydroxylamine hydrochloride (0.143 g, 2.07 mmol) in methanol (2.5 mi) was added solid sodium carbonate 108 g, 1.02 mmol). The resulting suspension was stirred at RT for wruin and the insoluble material removed by filtration. The filtrate was then combined with 3-benzylsulfonylamino-6-methyl-1-(4methylenecarboxamidomethyl- 1 -cyanopiperidinyl)-2-pyridinone (86.8 mg, 0. 190 mmol), stirred at RT for 3 h, concentrated in vacuo, and purified by preparative HPLC (C18, 0.1% TFA/H20,CH3CN gradient) to give the title compound (55 mg) as a white solid, m.p. 79-81oC: 1H NMR (CD30D) 6 1.25 2 1.84 3H), 2.33 3H), 3.04 (m, 2H), 3.16 2H), 3.78 (br d, J 13.4 Hz, 2H), 4.45 2H), 4.79 2 6.15 J 7.8 Hz, 1IH), 7.13-7.31 6H), 8.34 (br m, 1H); MS (FAB) 491 EXAMPLE XXVI Preparation of (+/-)-3-(ox-Methylbenzylsulfonylamino)-6-methyl- 1-(2amino-6-methyvl-5-methvlenecarboxamidomethlvridinvl)-2-pyvridinone 7qlsee I WO 97/01338 PCT/US96/10778 -66oo o N N N
CH
3 H O
NH
2 Step A: (+/-)-3-(a-Methylbenzylsulfonylamino)-6-methyl- 1 (t-buvyl-methylenecarboxy)-2-pyridinone A solution of lithium diisopropylamide in THF (0.393 M, 14.2 ml, 5.60 mmol, 2.2 ;quiv) was added to a solution of 3benzylsulfonylamino-6-methyl-1 -(t-butyl-methylenecarboxy)-2pyridinone (1.00 g, 2.55 mmol) in THF (20 mL) at -78 C under argon.
The resulting yellow suspension was warmed to 0°C and held at that temperature for 5 min, then cooled to -78°C and stirred for 15 min.
Iodomethane (0.800 mL, 12.8 mmol, 5.4 equiv) was added, and the reaction mixture was warmed to 0°C and stirred for 1 h. The product solution was partitioned between aqueous half-saturated ammonium chloride solution (150 mL) and ethyl acetate (150 mL). The aqueous phase was separated and extracted further with ethyl acetate (150 mL).
The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by flash column chromatography ethyl acetate in hexane initially, grading to 40% ethyl acetate in hexane) to afford a 10:1 mixture of (+/-)-3-benzylsulfonylamino-6methyl-l-a-(t-butoxycarbonylethyl)-2-pyridinone and methylbenzylsulfonylamino)-6-methyl- -(t-butyl-methylenecarboxy)-2pyridinone, respectively, as a colorless oil (410 mg, In the major product: IH NMR (CDC13) 4.82 (br, 1H, NCHCH3CO) replaces 4.89 2H, NCH2CO) in the spectrum of the starting material.
Step B: (+/-)-3-(ca-Methylbenzylsulfonylamino)-6-methyl- 1-(2- 2-pyridinone The mixture of t-butyl esters (410 mg, 1.01 mmol) was deprotected using the procedure of EXAMPLE IV, Step E. The mixture of resulting carboxylic acids was then coupled to 2-t-butoxycarbonyl- -I I- WO 97/01338 PCT/US96/10778 -67amino-5-rethylamino-6-methylpyridine (233 mg, 0.982 mmol) using the procedure of EXAMPLE IV, Step F. The major, undesired amide product was separated from the minor, desired component by fractional recrystallization from 60:40:5 hexane/ethyl acetate/methanol: 1H NMR (CDC13) selected peaks at 5 5.10 (br, 1H, CHCH3), 4.30 2H, BnCH2), 1.73 3H, J 7.0 Hz, CHCH3). The mother liquor was purified by preparative TLC (60:40:5 hexane/ethyl acetate/methanol) to give the desired amide product: 1i NMR (CDC13) selected peaks at 6 4.26 (q, 1H, J 7.1 Hz, CHCH3), 4.51 2H, NCH2), 1.70 3H, J 7.1 Hz, CHCH3). Treatment of the desired product with a solution of TFA/CH2C12 for 2.5 h at 23 'C followed by concentration afforded the title compound as a white solid (7 mg, mp 105-120'C, deformed): 1H NMR shows loss of BOC group; HRMS (FAB) Calc'd for C23H28N504S 470.1852; Found: 470.1862.
EXAMPLE XXVII Preparation of: 3-(3-Chlorobenzyl)sulfonylamino-6-methyl- -(2-amino- 6 methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone CI N N H 6 H I N NH 2 The title compound was prepared from 3-amino-6-methyl-l- (2-t-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone (75 mg, 0.187 rmnol) and 3-chlorobenzylsulfonyl chloride (84 mg, 0.356 mmol) using the procedure of EXAMPLE XIII, as an amorphous solid (TFA salt): 1 H NMR (DMSO) 8 2.25 3 2.41 3 4.17 J 5.5 Hz, 2 4.56 2 4.73 2 6.10 J Hz, 1 6.76 (br s, 1 7.16 J 7.5 Hz, 1 7.33 7.45 7.78 (br s, 1 8.73 1 MS (FAB) 490 (M+1) I I- I Iq I WO 97/01338 WO 9701338PCTIUS96/10778 68 Following the same procedure as above the following compounds were prepared: EXAMPLE XXVIII 0 S JQN N N 1H 0
H
N NH 2 3 Chloro benzy1) sulIfony lamin o-6 -methy I- 1 (2 -amino -6 -methyl1 -5 methylenecarboxamidomethylpvridinvl )-2-pyridinone (TEA salt); IH NMR (DMSO) 62.26 3H), 2.40 3H), 4.17 (d,J 5.7 Hz, 2 4.66 2 4.73 2 6.12 J 8.1 Hz, I 6.72 J 7.7 Hz, I 7. 18 J 7.5 Hz, 1 7.29 7.55 (in, 4 7.73 J 9.1 Hz, I 8.72 8.73 (in, 1 8.87 I MIS (FAB) 490 EXAMPLE XXIX Br', 0 N N H I!H 0- N
NH
2 3-(4-Bromobenzyl)sulfonylaminio-6-inethyl- 1 -(2-amino-6-inethyl-5methy lenecarboxami doinethylpy ri dini y -2-pyri dinone (TEA salt); IH NMR (DMS0) 62.25 (s,3 2.42 3H), 4.18 (d,J 5.7 Hz, 2 4.53 2 4.72 2 6.09 J 7.9 Hz, 1 6.79 J 7.5 Hz, I 7.15 J 7.5 Hz, I 7.30-7.5 1 (in, 4 7.79 (d,
LM*
WO 97/01338 PCT/US96/10778 -69- J 7.5 Hz, 1H), 8.63 IH), 8.70 8.78 1H); MS (FAB) 536 EXAMPLE XXX Preparation of 3-Benzylsulfonylamino-6-methyl- 1 -(2-amino-6-ethyl-5methylenecarboxamidomethylpyridinyi)-2-pyridinone 0 N NH 2 H H S' N N
N
Step A: 2-t-Butoxycarbonylamino-5-cyano-6-ethylpyridine To a stirred solution of 2-t-butoxycarbonylamino-5-cyano-6methylpyridine (0.50g, 2.145 mmol) in dry THF (15 ml) at -78°C was added n-BuLi (1.75 ml, 2.5 M in hexanes) dropwise. The solution turned deep red upon addition of the second equivalent of base. After 0.5 h methyl iodide (0.67 ml, 10.7 mmol) was added. After 1 h half saturated NH4C1 (15 ml) was added, the layers were separated and the aqueous layer was extracted with EtOAc (2 x 35 ml). The organic layers were combined and washed with saturated NaHCO3 (1 x 15 ml), water (1 x ml), and brine (1 x 15 ml), dried over MgSO4, filtered and concentrated to an oil. The crude product was purified by flash column chromatography (95:5; hexanes: ethyl acetate) to give the title compound (0.41 g) as a solid: 1 H NMR (CDC13) 6 1.29 J 7.5 Hz, 3 1.53 (s, 9 2.91 J 7.6 Hz, 2 7.40 (br s, 1H), 7.81 J 8.6 Hz, 1 H), 7.87 J 8.8 Hz, 1 H).
Step B: 2-t-Butoxycarbonylamino-5-aminomethyl-6-ethylpyridine The title compound was prepared from 2-tbutoxycarbonylamino-5-cyano-6-ethylpyridine (0.405g, 1.64 mmol) using the procedure of EXAMPLE V, Step as an oil (0.326 1
H
I Is III WO 97/01338 PCT/US96/10778 NMR (CDC13) 6 1.23 J 7.5 Hz, 3 1.48 (br s, 2H), 1.51 9 H), 2.72 J 7.5 Hz, 2 3.84 2H), 7.20 (br s, 1H), 7.58 J 8.4 Hz, 1 7.69 J 8.4 Hz, 1 H).
Step C: 3-Benzylsulfonylamino-6-methyl-l-(2-tmethylenecarboxamidomethylpyridinyl)-2-pyridinone DCC (50 mg, 0.242 mmol) was added to a stirred solution of 3-benzylsulfonylamino-6-methyl-1 -methylenecarboxy-2-pyridinone (79 mg, 0.235 mmol) and 2-t-butoxycarbonylamino-6-ethyl-5methylaminopyridine (60 mg, 0.239 mmol) in methylene chloride (2 ml).
After 16 h the reaction was filtered through celite and evaporated in vacuo to afford a pale yellow resin. The crude product was purified by flash column chromatography on silica (ethyl acetate/hexanes gradient, 60%-70% ethyl acetate) to give after trituration with ethyl acetate and hexanes the title compound (69 mg, 50.7%) as a white solid: IH NMR (CDC13) 5 1.18 J 7.5 Hz, 3 1.49 9 2.43 3 H), 2.68 J 7.5 Hz, 2 4.08 (br s, 1 4.21 2 4.38 J Hz, 2 4.47 2 6.05 J 7.7 Hz, 1 7.11-7.13 4 H), 7.18-7.21 2 7.39 J 7.7 Hz, 1 7.52 J 8.4 Hz, 1 H), 7.62 J 8.4 Hz, 1 8.30 (br s, 1 H).
Step D: 3-Benzylsulfonylamino-6-methyl- 1 -(2-amino-6-ethyl-5methylenecarboxamidomethvlpyridinvl)-2-pyridinone A solution of 3-benzylsulfonylamino-6-methyl-l-(2-t- 2-pyridinone (69 mg, 0.121 mmol) in ethyl acetate was cooled to -78° C.
HCI gas was bubbled through solution for approximately 8 min and warmed to 0° C. After 2 h the reaction solution was degassed with Argon and was evaporated in vacuo. Ethyl acetate was added and solution was again evaporated in vacuo to a solid. Trituration with ethyl acetate and subsequent filtration gave the title compound (38.3 mg, 62.5%) as a tan solid: 1H NMR (CD30D) 6 1.30 J 7.6 Hz, 3 2.32 3 2.85 J 7.6 Hz, 2 4.13 2 4.35 J 5.7 Hz, 2 4.83 2 H), WO 97/01338 WO 9701338PCT/US96/10778 -71 6.15 J 7.7 Hz, I 6.82 J =9.0 Hz, I 6.95 J 9.3 Hz, I 7.25-7.32 (in, 5 7.93 (dd, J =9.2 and 2.0 Hz, 2 8.74 (br m, I MS (FAB) 470 EXAMPLE XXXI Preparation of 2-Cyclohexylethylaminu-6-methy 1-1-(2-amin o-6-methy I- 5-methylenecarboxamidomethylpvyridinvl)-2-pvyri dinone
NH
2 H H Step A: 2-Cyclohexylethiylamino-6-methyl- 1 butoxycarbonylIamino -6 -methyl1 -5 meth ylenecarboxam ido meth y1pvri dinvi D-2 -pyridin one To a solution of cyclohexylacetaldehyde (25.9 mg, 0.206 mmol) and 2-amino-6-methyl- 1 -(2-t-butoxycarbonylamino-6-inethyl-5meth ylenecarbo xami domethylpyri din yl -pyri din one (75 mg, 0. 187 inmol) in methanol (5 ml) was added aluminum foil (37.8 mg, 1 mi-nol) and mercury(H) chloride (5.1 mg, .0 187 inmol). After 16 h the reaction was filtered and concentrated in vacuo. The residue was dissolved in EtOAc, washed with a 5% solution of sodium potassium tartrate (2 x 20 ml)) and brine (1 x 20 ml). The organic layer was dried (Na2SO4) and concentrated in vacuo The residue was purified by flash column chromatography on silica (eluting with 1.5:1 EtOAc:CHCI3) to give the title compound (56 mg, 1 H NMR (400 MHz, CDCI3) 8 0.91 -1.00 (in, 2 1. 13-1.22 (in, 3 1.35-1.43 (mn, 1 1.50 9 H), 1.51-1.57 (mn, 3 1.62-1.77 (in, 4 2.35 3 2.36 3 3.04- 3.08 (mn, 2 4.33 J 5.8 Hz, 2 4.59-4.67 (in, I 4.75 (br s,)2 WO 97/01338PCJS6107 PCT/US96/10778 72 6.05 J 7.8 Hz, I 6.15 J 7.5 H-z, I 7.11-7.20 (in, 2 7.38 J 8.4 Hz, 1 7.65 J 8.4 Hz, I H).
Step B: 2-Cyclohexylethylamino-6-methyl- 1 -(2-amino-6-methyl-5meth ylenecarboxamidomethy lpyri dinfl)-2-pyridin one A solution of 2-cyclohexylethyl amino -6-rnethyl 1-(2-t- -methjylenecarboxarnidomethyl pyridinyl)-2-pyridinone (56 mg, 0. 109 mm-ol) in EtOAc (35 ml) at 0 0
C,
was saturated with HCI gas. This solution was warmed to room temperature and after 30 min the solution was concentrated in vacuo.
The residue was partitioned between EtOAc and 5% aqueous NaOH.
The EtOAc layer was washed with brine, dried (Na2S 04) and concentrated in vacuo. The crude product was purified by flash column chromatography on silica (eluting with 1.5% MeGH/chioroform saturated with ammonia) to give the title compound as a colorless solid (25 mg, 1 H NMR (400 MHz, CDCI3) 8 0.93-0.99 (in, 2H), 1. 16-1.25 (in, 3H), 1.33-1.44 (mn, IH), 1.48-1.60 (in, 3H), 1.63-1.80 (in, 4H), 2.31 (s, 3H), 2.35 3H), 3.05 (dd, J 13.0 and 7.14 Hz, 2H), 4.27 J 5.7 Hz, 2H), 4.32 (br s, 2H), 4.63 (br t, I 4.74 2H), 6.03 J 7.9 Hz, 1lH), 6.14 J 7.3 Hz, I 6.28 .J 8.2 Hz, I 6.95 (br d, I1H), 7.24 J 6.9 Hz, I MIS (FAB) 412 (M+1 EXAMPLE XXXII Preparation of 3-Benzylsulfonylamnino- 6-cyclopropyl- I -(2-amino-6meth yl-5 -methylenecarboxami domethylpyridin l -pyridin one 0 SNN
NN
H
0
HI
0
~NH
2 WO 97/01338 PCTIUS96/10778 -73- Step A: 3-N,N-Dimethvlaminoethenylcyclopropvl ketone A mixture of cyclopropyl methyl ketone (5.88 ml, 59 mmol) and N,N-dimethylformaldehyde dimethyl acetal (7.83 ml, 59 mmol) was heated in the presence of a catalytic quantity of p-toluenesulfonic acid for 48 hours. The resulting crude sample of the title compound (a pale yellow oil) was used in subsequent reactions without further purification: I H NMR (CDC13) 6 0.74 2 1.00 2 1.75 1 3.48 (s, 3 3.50 3 5.20 I 7.55 I H).
Step B: 6-Cvclopropyl-3-nitro-2-( H)-pyridinone A mixture of crude P-N,N-dimethylaminoethenylcyclopropyl ketone (12 g, 86 mmol), nitroacetamide (9 g, 86 mmol) and aqueous piperidinium acetate (10 ml) [prepared from glacial acetic acid (42 ml), water (100 ml) and piperidine (72 ml)] was stirred at room temperature overnight. Following dilution with water (20 ml), the yellow precipitate was isolated via filtration and drying in vacuo to yield 5.30 g of the title compound: 1 H NMR (CDC13) 6 1.15 2 1.36 2 H), 2.10 I 6.02 (br d, J 8.0 Hz, 1 8.41 J 8.0 Hz, 1 H).
Step C: 3-Nitro-6-cyclopropyl- -(t-butyl-methylenecarboxy)-2pyridinone Solid 6-cyclopropyl-3-nitro-2-( H)-pyridinone (1.4 g, 7.78 mmol) was added in small portions to a suspension of sodium hydride (260 mg, 10.8 mmol) in THF (30 ml) at room temperature. After stirring the resulting solution for 20 min, tert-butylbromoacetate (4 ml, 27 mmol) was added. The mixture was stirred for an additional 30 min. then heated at 55°C for 15 hrs. After cooling to room temperature the THF was evaporated in vacuo and ice carefully added to the residue to destoy any excess sodium hydride. The resulting miture was extracted with 2:1:1 ethyl acetate:ether:chloroform and the extracts dried over magnesium sulfate. Filtration and evaporation of the filtrate gave a yellow oil as a 3:1 mixture of N and O-alkylated products respectively. Flash column chromatography eluting with 1:1 hexane/ethyl acetate gave 1.59 g of the title compound as a yellow crystalline solid: 1 H NMR (CDCI3) 6 0.94 I ~I WO 97/01338 PCT/US96/10778 -74- 2 1.18 2 1.49 9 1.79 1 5.04 2 6.10 J 8.1 Hz, 1 8.33 J 8.1 Hz, 1 H).
Step D: 3-Amino-6-cyclopropyl- 1 -(t-butyl-methylenecarboxy)-2pyridinone A mixture of 3-nitro-6-cyclopropyl- -(t-butyl-methylenecarboxy)-2-pyridinone (760 mg, 2.58 nimol) and platinum oxide (250 mg) in ethanol (30 ml) was stirred at 0° C under an atmosphere of hydrogen for 3 hours. Following removal of most of the catalyst by filtration through a bed of Celite, the filtrate was concentrated and the rsidue purified by flash column chromatography eluting with 2:1 hexane/ethyl acetate. This yielded 506 mg of product as a very viscous orange gum: 1 H NMR (CDC13) 6 0.67 2 0.89 2 1.49 9 1.63 1 4.07 (br s, 2 4.99 2 5.91 (dd, J 1.2 and 7.4 Hz, 1 6.47 J 7.4 Hz, 1 H).
Step E: 3-Benzylsulfonylamino-6-cyclopropyl- 1-(t-butylmethylenecarboxy)-2-pyridinone The title compound was prepared from 3-amino-6-cyclopropyl-1 -(t-butyl-methylenecarboxy)-2-pyridinone according to the procedure of EXAMPLE V, Step D: 1 H NMR (CDC13) 8 0.76 2 H), 1.01 2 1.52 9 1.68 1 4.31 2 4.98 2 H), 5.98 J 7.7 Hz, I 7.25-7.34 6 H).
Step F: 3-Benzylsulfonylamino-6-cyclopropyl-l-methylenecarboxy- 2-pyridinone The title compound was prepared from 3-benzylsulfonylamino-6-cyclopropyl- I-(t-butyl-methylenecarboxy)-2-pyridinone according to the procedure of EXAMPLE V, Step E: I H NMR (CDC13) 5 0.77 2 1.03 2 1.74 1 4.36 2 5.06 2 H), 6.04 J 7.7 Hz, I 7.30-7.39 6 H).
WO 97/01338 WO 9701338PCTIUS96/I 0778 75 Step G: 3-Benzylsulfonylamino-6-cyclopropyl- I -(2-amino-6methyl-S -methylenecarboxamidomethylpyridinyl pyridinone The title compound was prepared from 3-benzylsulfonylammno-6-cyclopropyl-l1-methylenecarboxy-2-pyridinone and 2-tbutox ycarbonylamino -6 -methyl1-5 -methylIaminopyri dine essentially according to the procedure of EXAMFLE V, Step F: 1 NMR (CD3OD) 6 0.77 (in, 2 0.99 (in, 2 1.82 (in, 1 2.51 3 4.33 2 H), 4.44 2 5.03 2 6.11 J 7.9 Hz, i 6.79 J 9.1 Hz, 1 7.26-7.33 (in, 6 7.87 J 9.1 Hz, I MS (FAB) 482 EXAMPLE XXXIfl Preparation of 3-Benzylsulfonylamino-6-propyl-lI-(2-amino-6-methyl- 5-methylenecarboxainidomethvlpyridinyl)-2-p2vridinone 0
H
0 H A NH 2 Step A: 3-Amino-6-propyl-2-( H)-pyridinone A mixture of 6-cyclopropyl-3-nitro-2-(IH)-pyridinone (2 r.
13.3 mmol) and 10% palladium on carbon (600 mg) in ethyl acetate (iOC ml) was stirred at room temperature under an atmosphere of hydrogen overnight. The catalyst was removed by filtration through a bed of Celnw and the filtrate concentrated to yield 1 .63 g of product as a white microcrystal line solid. 1 NMR (CDCI3) 6 0.94 J 7.3 Hz, 3 1 .67 (in, 2 2.49 J 7.5 Hz, 2 4.00 (br 5.88 J 7.1 Hz, I H), 6.59 J 7.1 Hz, 1 H).
WO 97/01338 PCT/US96/10778 -76- Step B: 3-Benzvloxycarbonylamino-6-propyl-2-(IH)-pyridinone Benzyl chloroformate (1.8 ml, 12.6 mmol) was added to a solution of 3-amino-6-propyl-2-(1H)-pyridinone (1.63 g, 10.8 mmol) in a mixture of dioxane (25 ml) and IN NaOH at 0°C. Within minutes a white precipitate formed. The reaction mixture was stirred at the same temperature for 1 hr then at room temperature for an additional hour. The reaction mixture was diluted with watei and extracted with ethyl acetate then methylene chloride. Each extract was washed with brine then combined and dried over magnesium sulfate. Removal of the solvents in vacuo gave a yellow semi-solid which was a mixture of starting material and product. This was redissolved in a mixture of dioxane (24 ml) and aqueous sodium bicarbonate (12 ml) and cooled to 0°C. Benzyl chloroformate (1.5 ml, 10.5 mmol) was once again added and after stirring for 30 min, the reaction mixture was allowed to stir at room temperature for 3 h. After dilution with water, the precipitate was filtered off and washed thoroughly, first with water and then with ether. Drying gave 2.64 g of the title compound as a white powder: 1 H NMR (CDC13) 6 0.96 J 7.3 Hz, 3 1.68 2 2.52 J 7.5 Hz, 2 5.22 2 6.07 J 7.5 Hz, 1 7.34-7.43 4 7.68 1 8.05 (br d, J 5.3 Hz, 1 H).
Step C 3-Benzyloxycarbonylamino-6-propyl-1 -(t-butylmethylenecarboxy)-2-pyridinone Solid 3-benzyloxycarbonylamino-6-propyl-2-(1 H)pyridinone (2.64 g, 9.3 mmol) was added in small portions to a suspension of sodium hydride (269 mg, 11.2 mmol) in THF (30 mi) at 0° C. The reaction mixture was the stirred at room temperature for 20 min by which time an almost completely homogeneous solution had been obtained. Tert-butyl-bromoacetate (2.2 ml, 14.9 mmol) was then added.
Within minutes a white precipitate started forming. Stirring was continued overnight, then the THF was evaporated in vacuo. Ice was carefully added to the residue to destoy any excess sodium hydride.
Brine was added and the resulting miture was extracted with 2:1:1 ethyl acetate/ether/chloroform and the combined extracts were dried over WO 97/01338 PCT/US96/10778 -77magnesium sulfate. Filtration and evaporation of the filtrate gave a cream solid which was purified by flash column chromatography eluting with 3:1:1 hexane/chloroform/ethyl acetate. This gave 2.38 g of the title compound as a white crystalline solid: 1 H NMR (CDC13) 5 1.00 J 7.3 Hz, 3 1.48 9 1.64 2 2.46 J 7.6 Hz, 2 4.72 2 5.20 2 6.08 J 7.7 Hz, 1 7.31-7.40 4 7.77 1 7.97 (br d, J 7.0 Hz, 1 H).
Step D: 3-Amino-6-propyl-1 -(t-butyl-methylenecarboxy)-2pyridinone 3-Benzyloxycarbonylamino-6-propyl- I-(t-butylmethylenecarboxy)-2-pyridinone (2.38 g, mmol) was dissolved in a 1:1 mixture of ethyl acetate and ethanol (100 ml) and then stirred in the presence of 20% palladium hydroxide on carbon (800 mg) under an atmosphere of hydrogen for 2 h. The catalyst was removed by filtration through Celite and the filtrate concentrated to give the title compound as an orange oil (1.65 1 H NMR (CDC13) 50.98 J 7.3 Hz, 3 1.47 9 1.57 2 2.40 J 7.7 Hz, 2 4.73 2 5.91 J 7.3 Hz, 1 6.55 J 7.3 Hz, 1 H).
Step E: 3-Benzylsulfonylamino-6-propyl- 1 -(t-butyl-methylenecarboxy)-2-pyridinone The title compound was prepared from 3-amino-6-propyl-l- (t-butyl-methylenecarboxy)-2-pyridinone according to the procedure of EXAMPLE V, Step D: Step F: 3-Benzylsulfonylamino-6-propyl- 1 -methylenecarboxy-2pyridinone The title compound was prepared from 3benzylsulfonylamino -6-propyl-1 -(t-butyl-methylenecarboxy)-2pyridinone according to the procedure of EXAMPLE V, Step E: WO 97/01338 PCT/US96/10778 -78- Step G: 3-Benzylsulfonylamino-6-propyl- 1-(2-amino-6-methyl-5methylenecarboxamidomethylpyridiny l)-2-pyridinone The title compound was prepared from 3benzylsulfonylamino-6-propyl- I -methylenecarboxy-2-pyridinone and 2t-butoxycarbonylamino -6-methyl-5-methylaminopyridine essentially according to the procedure of EXAMPLE V, Step F: IH NMR (CDCI3) 1.01 J 7.3 Hz, 3 1.63 2 2.51 3 2.57 2H), 4.32 J 5.7 Hz, 4.44 2H), 4.78 2 6.14 J 7.7 Hz, 1 H), 6.79 J 9.0 Hz, 1 7.26-7.34 6H), 7.89 J 9.0 Hz, 1 H).
EXAMPLE XXXIV Preparation of 3-Benzyloxycarbonylnethylamino-6-methyl- I1-(2-amino- 6-methl-5-methlenecarboxamidomethylpyridinyl)-2-pyridinone Nj 0 N,0 N NN O O
HHNH
2 Step A: 3-Benzyloxycarbonylmethylamino-6-methyl- 1 -(t-butylmethvlenecarbox)-2-pyridinone A solution of 3-amino-6-methyl- I -(t-butylmethylenecarboxy) -2-pyridinone (1.04 g) and N,Ndiisopropylethylamine (0.88 ml, 5.03 mmol) in DMF was treated at 0' C with benzyl bromoacetate (0.80 ml, 5.03 mmol). The reaction mixture was allowed to warm gradually to room temperature and was then stirred overnight. The volatiles were removed under reduced pressure and the residue dissolved in the minimum quantity of chloroform. This solution was then partitioned between ethyl acetate and saturated sodium bicarbonate. The organic phase was separated and washed with water and then brine. Drying and removal of the solvents gave a dark yellow oil which was purified by preparative HPLC: IH NMR (CDC13) 6 1.47 -I c L WO 97/01338 PCT/US96/10778 79 2.20 3 3.91 2 4.76 2 5.20 2 5.98 J =7.4 Hz, 1 6.09 J 7.4 Hz, 1 7.35 (in, 5 H).
Step B: 3-Benzyloxycarbonylmethylarnino-6-methyl- I -methylenecarboxy-2-pyridinone The title compound was prepared from 3benzyloxycarbonyl-methylamino-6-methyl- I -(t-butylmethylenecarboxy)-2-pyridinone according to the procedure of EXAMPLE V, Step E: I H NMR (CDCI3) 862.27 3 3.99 2 H), 4.81 2 5.21 2 6.07 J 7.5 Hz, I 6.60 J 7.5 Hz, 1 7.35 (in, 5 H).
Step C: 3-Benzyloxycarbonylmethylamino-6-methyl- I -(2-amino-6- -methylenecarbo xamidomethy I-pyri din yl)-2 pyridinone The title compound was prepared from 3benzyloxycarbonyl-methylamino-6-rnethyl- 1 -methylenecarboxy-2pyridinone and 2-t-butoxy-carbonylamino-6-inethy 1-5 methy laminopyri dine essentially according to the procedure of EXAMPLE V, Step F: I H NMR (CDCI3) 6 2.32 3 2.36 3H), 3.91 J 6.2 Hz, 2 4.26 J 5.7 Hz, 2 4.73 (in, 2 5.20 (in, 2 6.00 J 7.3 Hz, I 6.09 J 7.3 Hz, I 6.29 J 8.6 Hz, I 7.35 (in, 5 MIS (FAB) 450 EXAMPLE XXXV Preparation of 3-(Ethyi L-phenyl al anylI)-6-methyl-I 1 -(2-amino-6-methylI )-2-pyridinone EtO 2 C0 P h N N NN 0 H
NH
2 WO 97/01338 WO 9701338PCTIUS96/I 0778 80 Step A: 3-(Ethyl L-phenylalanyl)-6-methyl- I -(t-butyl-methylenecarboxy),2-pyridinone A solution of ethyl (R)-2(trifluoromethylsulfonyloxy)-3phenylpropionate (1.7 g, 4 mmol) in methylene chloride (5 ml) was added at room temperature to a solution of 3-amino-6-methyl- 1 -(t-butylme-ihylenecarboxy)-2-pyridinone (601 mg, 2.5 mmol) and N,Ndiisopropylethylamine (0.7 ml, 4 mmnol) in methylene chloride (10 ml).
After stirring for 88 hours the reaction mixture was washed with saturated sodium bicarbonate and dried over magnesium sulfate.
Filtration, evaporation of the solvents, and chromatography on silica of the residue eluting with 7:3 hexane:ethyl acetate, gave the title compound as a yellow oil (740 mg).
Step B: 3-(Ethyl L-phenylalanyl)-6-methyl- I -methylenecarboxy-2pyridinone The title compound was prepared from 3-(ethyl Lphenylalanyl)-6-methyl- I -(t-buty 1-methylenecarboxy )-2-pyri dinone according to the procedure of EXAMPLE V, Step E: Step C: 3-(Ethyl L-phenylalanyl)-6-methyl- I -(2-amino-6-methyl-5methylenecarboxamidomethv lpyri dinl I)-2-pyri din one The title compound was prepared from 3-(ethyl Lphenylalanyl)-6-methyl- I -methylenecarboxy-2-pyridinone and butoxycarbonylamino-6-methyl -5-m-ethylaminopyridine essentially according to the procedure of EXAMPLE V, Step F: I HNMR (CDCI3) 6 1. 16 J 7.1 Hz, 3H), 2.24 3 2.49 3H), 3.13 (in, 2 4.09 (q, J 7.1, 13.9 Hz, 2 4.28 (in, 2 4.77 2H), 6.01 J 7.5 Hz, I HI), 6.33 J 7.5 Hz, 1 6.79 J 9.0 Hz, 1 7.22 (in. 5 H), 7.83 J 9.0, 1lH); MIS (FAB) 47 8 EXAMPLE XXX VI Preparation of 3 -(Ethyl D-phenylalanyl )-6-.methy I- I -(2-amino-6-methyl )-2-pyridinone
N
WO 97/01338 PTU9/07 PCT/US96/10778 EtO 2 C 0 o
NH
2 3-(Ethyl D-phenylalanyl)-6-methyl- I -k2-amino-6-methyl-5-methylenecarboxamidomethylpyri dinvi )-2-pyridinone The title compound was prepared according to the procedure of EXAMPLE XXXV, employing ethyl 2(trifluoromethylsulfonyloxy)-3-phenylpropionate.
EXAMPLE XXX VII Preparation of 3-Benzylsulfonylamino-6-cyclopropyl- I methylenecarboxamidomethylpyridinyl )-2-pyridinone 02
N
SN N "N H 0 H tI
N
The title compound was prepared from 3-benzylsulfonylamino-6-cyclopropyl -1-methylenecarboxy-2-pyridinone and 2-tbut ox ycarbo nylIamino-5 -methylIamninopyri dine essentially according to the procedure of EXAMPLE V, Step F: IH NMR (CD3OD) 60.76 (in, 2 1.00 (in, 2 1.83 (in, I 4.34 2 4.44 2 5.04 2 6.13 J 7.8 Hz, I 6.96 J 9.0 Hz, 1 7.24-7.34 (in, 6 7.81 1 7.90 J 8.6 Hz, 1 MIS (FAB) 468 EXAMPLE XXX VI Preparation of 3-(4-Chlorobenzyi)sulfonylamino-6-cyclopropyl- 1 amin o-6-meth vl-5 -methylenecarboxami domethy Ipyri din y -2-pyri dino ne WO 97/01338 WO 9701338PCT[US96/10778 82 02 0 I t_,_NN
NN
H
0 H
NH
2 The title compound was pi. pared from 3-amino-6-cyclo propyl -1 -(t-butyl-methylenecarboxy)-2--pyridinone, 4-chlorobenzyl su Ifony 1 chloride and 2-t-butoxycarbonylamino-6-methyl-5-methylaminopyridine essentially according to the procedure of EXAMPLE V, Steps D-F: IH NMR (CD3OD) 5 0.77 (in, 2 1.00 (in, 2 1.8 1 (in, I 2.52 3 H), 4.33 2 4.43 2 5.03 2 6.09 J 7.7 Hz, I 6.77 J 9.1 Hz, I 7.20 J 8.5 Hz), 7.25 J 8.5 Hz), 2 7.33 J 7.7 Hz, 1 7.89 J 9.1 Hz, I MIS (FAB) 516 EXAMPLE XXXIX Preparation of 3-(4-Chlorobenzyl)sulfonylamino-6-cyclopropyl- 1 amin o-5 -meth y Ienecarbox amidomethy Vlpri din yl)-2 -pyridinone S, Nj SN N
H
0
HNH
2 Step A: 3-(4-Chlorobenzyl)sulfonylamino-6-cyclopropyl- 1 -methylenecarboxarnidomethyI pyridinyl)-2-pyridinone The title compound was prepared from 3-(4-chlorobenzyl)-sulfoiiylamino-6-cyclopropyl-l1-methylenecarboxy-2-pyridinone and 2-tbutoxycarbonylIamino -5 -methy laminop yridine essentially according to the procedure of EXAMPLE V, Steps D-F: IlH NMR (CD3OD) 6 0.78 (in, 2 H), 1. 01 (in, 2 1. 83 (in, 1 4.3 5 2 4.4 3 2 5.05 2 6. WO 97/01338 W097/1338PCT[US96/1 0778 83 J 7.7 Hz, I 6.95 J 9.3 Hz, I 7.22 (in, 4 7.35 J 7.7 Hz, I 7.81 I 7.91 (dd, J 1.8 and 9.3 Hz, I MS (FAB) 502 EXAMPLE XL Preparation of 3 -CyclohexylmethylsuIf onylIamino- 6-cyclIopropyl -(42amino-6-meth yl-5 -meth ylenecarbox ami dometh ylpyri din y 1)-2-pyri dinone 02 0 02 Nj SN NN H H NH 2 The title compound was prepared from 3-amino-6-cyclopropyl- I (t-butylI-methy lenecarbox y) -2-pyri din one, cyclohexylmethylsulfonyl chloride and 2-t-butoxycarbonylamino-6- -methylamninopyri dine essentially according to the procedure of EXAMPLE V, Steps D-F: I H NMR (CD3OD) 8 2.51 3 2.97 J 5.8 Hz, 2 4.31 2 5.07 2 6.20 J 7.7 Hz, I 6.78 J 9.0 Hz, I 7.46 J 7.7 Hz, I 7.88 J 9.0 Hz, I H); MS (FAB) 488 EXAMPLE XLI Preparation of 3-Cyclohexylmethylsulfonylamino-6-cyclopropyl -14-2amin o-5-meth ylenecarboxami domethylpyridin y -2-pVyrid inone N NN H H NH 2 WO 97/01338 WO 9701338PCTfUS96/10778 84 The title compound was prepared from 3-cyclohexylmtethylsulfonylamnino-6-cyclopropyl- I -methylenecarboxy-2-pyridinone and 2-t -rnethyl aminopyri dine essentially according to the procedure of EXAMPLE V, Step, F: I1 NMR (CD3OD) 5 2.98 J 5.8 Hz, 2 4.32 2 5.09 2 6.21 J 7.8 Hz, 1 6.97 J 9.3 Hz, 1 7.45 J 7.8 Hz, I 7.81 1 7.89 J= 1.8 Hz, I H) 7.92 J 1.8 Hz, I -MS (FAB) 474 EXAMPLE XLII Preparation of 3-Cyclohexylmethyisulfonylamino-6-methyl- I -(2-amino- 6-meth y 1-5 -meth ylenecarboxam idomethylp ri din y 1)-2-pyri dinone 02 0 02 N N N
H
0 HNH 2 The title compound was prepared from 3 -amino-6-meth yI- I (t-butyl -methylenecarboxy)-2-pyridinone, cyclohexylmethylsulfonyl chloride and 2-t-buto xycarbonylamino-6-methyl1-5 -meth yl amin opyri dine essentially according to the procedure of EXAMPLE V, Steps D-P: IH NMR (CD3 OD) 5 0.99-1.91 (in, 10 2.3 3 3 2.51 3 3.03 J 6.6 Hz, 2 4.30 2 6.23 J 7.5 Hz, I 6.80 J 9.0 Hz, 1 7.44 J 7.5 Hz, 1 7.86 J 9.0 Hz, I MS (FAB) 462 EXAMPLE XLfI Preparation of 3-Cyclohexytmethylsulfonylamino-6-methyl- I -(2-amino- -methyl enecarboxainidom ethy lpyri dinyl) -2 -pyridi none WO 97/01338 WO 9701338PCT1US96/10778 85 02 f0 (D AN N
H
0 H NH 2 The title compound was prepared from 3-cyclohexylmethylsu lfonylamino-6-methyl- I -methylenecdrboxy-2-pyridinone and 2-tbutox ycarbonylIamino -5 -methyl ani nopyri dine essentially according to the procedure of EXAMPLE V, Step F: I HNMRZ (CD3OD) 862.35 3 2.97 J 6.0 Hz, 2 4.31 2 4.84 2 6.24 J 7.6 Hz, I 6.98 J 9.1 Hz, 1 7.44 J 7.6 Hz, 1 7.79 I 7.90 (dd, J 2.1 and 9.1 Hz, I MS (FAB) 448 EXAMPLE XLIV Preparation of 3-(2-Cyclohexylethyl)sulfonylamino-6-methyl- 1 amin o-6-methyl -5 -methylenecarbox amidometh ylpyri dini pyridinone 02 0 S N
N
H4 0 H
NH
2 The title compound was prepared from 3 -amino-6-methyl-1I (t -butylI -methylIenecarbox y) -2-pyri din one, 2-cyclohexylethylsulfonyl chloride and 2-t-butoxycarbonylamin o-6-methy 1-5 -methylaminopyri dine essentially according to the procedure of EXAMPLE V, Steps D-F: I H NMR (CD3OD) 6 2.34 3 2.51 3 3.09 (in, 2 4.31 (in, 2 4.82 2 6.23 J 7.6 Hz, 1 6.81 J 9.0 Hz, I 7.45 J 7.6 Hz, 1 7.87 J 9.0 Hz, 1 MS (FAB) 476
EXAMPLEXL-V
Preparation of 3-(2-Cyclohexylethyl)sulfonylamirio-6-methyl- 14-2- )-2-pyridinone WO 97/01338 WO 9701338PCT/US96/10778 86 02 jN 0 C NN NN
H
0 H NH 2 Step A: 3-Cyclohexylethylsulfonyamino-6-methyl- 1 -(2-t-butoxy- -methylenecarboxamidomethylpyri dinyI) 2-pyridinone The title compound was prepared from 3-cyclohexylethylsulfonylamino-6-methyl- 1 -methylenecarboxy-2-pyri din one and 2-t butoxycarbo nylIamino -5 -methylaminopyri dine essentially according to the procedure of EXAMPLE V, Step F: I HNMR (CD3OD) 8 2.35 3 H), 3.06-3.12 (in, 2 4.32 2 4.84 2 6.24 J 7.6 Hz, I H), 6.98 J 9.3 Hz, 1 7.46 J 7.6 Hz, I 7.80 1 7.90 (dd, J =2.1 and 9.3 Hz, 1 MS (FAB) 462 EXAMPLE XLVI Preparation of -(2-tetrahydropyraniylinethyl su lfony lam ino)-6methyl- I -(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl 2-p2yridinone 02 0 0o- S N N
~NH
2 The title compound was prepared from 3-amino-6-methyl-lI- (t -bu tylI -m ethy lenecarboxy) -2-pyri din one, 2-tetrahydropyranylmethy Isulfonyl chloride and 2-t-butoxycarbonylamino-6-methyl-5methylaminopyridine essentially according to the procedure of EXAMPLE V, Steps D-F: I H NMR (CD3OD) 5 1. 18- 1.78 (in, 6 2.33 3 2.50 3 3.25 (in, 3 3.80 J 10.8 Hz, 2 4.30 (s,)2 WO 97/01338 WO 9701338PCTT Y-96/10778 87 4.81 2 6.22 J 7.6 Hz, 1 6.78 J 9.0 Hz, I 7.45 J 7.6 Hz, I 7.85 J 9.0 Hz, I MS (FAB) 464 (M+1 EXAMPLE XL VII Preparation of 3-Butylsulfonylamino-6-methyl- I -(2-amnino-6-methyl-5meth ylenecarbo xami domethvylp2yri dinv y0-2-pvyri dinone N2
N
H 0 H I NH The title compound was prepared from 3 -amino-6-methyl- I- (t-butylI-methylenecarboxy) -2-pyri dinlonle, 3-butylsulfonyl chloride and 2t-butox ycarbonylIamino -6 -methyl -5 -methylIamin opyri dine essentially according to the procedure of EXAMPLE V, Steps D-F: I HNMR (CD3OD) 5 0.89 J 7.3 Hz, 3 1.38 (in, 2 1.72 (in, 2 2.33 3 2.50 3 3.08 (mn, 2 4.30 2 4.82 2 6.23 (d, J 7.6 Hz, I 6.80 J 9.2 Hz, I 7.45 J 7.6 Hz, I 7.86 J 9.2 Hz, I MS (FAB) 422 EXAMPLE XLVIII Preparation of 3-(3-Methyl- 1 -butylsulfonylamino)-6-methyl- 1 amin o-6-meth y1-5 -meth ylenecarboxam idoieth y 12ri din y 1) 2 -12yrd ilone N z SN NN H 0 NH2 The title compound was prepared from 3-amino-6-methyl- I1- (t-butyl-methylenecarboxy)-2-pyridinofle, 3-methyl- I -butyls u fonyl chloride and 2--uoyabnlmn--ety--ehlmnpndn
-M
WO 97/01338 WO 9701338PCT/US96/I 0778 88 essentially according to the procedure of EXAMPLE V, Steps D-F: I H NMR (CD3OD) 560.86 J 4.6 Hz, 6 1.63 (in, 3 2.33 3 H), 2.51 3 3.12 (in, 2 4.30 2 4.82 2 6.23 J 7.3 Hz, I 6.80 J 9.3 Hz, I 7.45 J 7.3 Hz, I 7.87 J= 9.3 Hz, 1 MIS (FAB) 436 EXAMPLE IL Preparation of 3-Pentylsulfonylamino-6-methyl- I -(2-amino-6-methyl- 5-methylenecarboxamidomethy' -),yridinyl 2-pyridinone 02 0 N, N N NN I!11
NH
2 The title compound was prepared from 3-amino-6-methyl-I 't-butyl -methylenecarboxy) -2-pyridin one, pentylsulfonyl chloride and 2- 1 -butox y-carbonylam ino-6 -methyl1-5 -methylamninopyri dine essentially according to the procedure of EXAMPLE V, Steps D-F: I H NMR (CD3OD) 6 0.87 J 6.8 Hz, 3 1.31 (in, 4 1.74 (in, 2 2.34 3 2.50 3 3.08 (in, 2 4.31 2 4.83 2 6.23 (d, J 7.6 Hz, I 6.79 J 9.1 Hz, I 7.45 J 7.6 Hz, I 7.86 J 9.1 Hlz, 1 MS (FAB) 436 EXAMPLE L Preparation o~f 3-[2-(4-Morpholinoethyl)sulfonylamino]-6-inethyl-l1-(2amin o-6-ineth yl-5 -meth ylenecarbox aindoinethyl pyri din y 1)-2-pyridinone 02 0 UjH 0 HNH 2 WO 97/01338 PCT/US96/10778 89- Step A: 3-Vinylsulfonylamino-6-methyl- I-(t-butylmethylenecarboxy)-2-pyridinone 2-Chloroethylsulfonyl chloride (513 mg, 3.1 mmol) was added to a solution of 3-amino-6-methyl-1-(t-butyl-methylenecarboxy)-2pyridinone in pyridine (50 ml) and the resulting mixture was stirred at room temperature overnight. The solvent was evaporated in vacuo and the residue was redissolved in chlorofoim, washed with water, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by preparative HPLC to give the title compound.
Step B: 3-[2-(4-Morpholinoethyl)sulfonylamino]-6-methyl- butyl-methylene-carboxy)-2-pyridinone Morpholine (106 Jl, 1.2 mmol) was added to a stirred solution of 3-vinylsulfonylamino-6-methyl- -(t-butylmethylenecarboxy)-2-pyridinone (200 mg, 0.61 mmol) in mechylene chloride (50 ml). After 64 h the reaction mixture was washed with sodium carbonate, dried (magnesium sulfate) and evaporated in vacuo.
IH NMR (CDC13) 5 2.36 3 2.52 3H), 3.62 4 3.88 (s, 2H), 4.32 2 6.35 J 7.7 Hz, 1 6.81 J 8.8 Hz, 1 H), 7.54 J 7.7 Hz, 1 8.84 J 8.8 Hz, I MS (FAB) 479 EXAMPLE LI IN VITRO ASSAY FOR DETERMINING PROTEINASE INHIBITION Assays of human a-thrombin and human trypsin were performed by the methods substantially as described in Thrombosis Research, Issue No. 70, page 173 (1993) by S.D. Lewis et al.
The assays were carried out at 25 0 C in 0.05 M TRIS buffer pH 7.4, 0.15 M NaCI, 0.1% PEG. Trypsin assays also contained 1 mM CaCl2. In assays wherein rates of hydrolysis of a p-nitroanilide (pna) substrate were determined, a Thermomax 96-well plate reader was used was used to measure (at 405 nm) the time dependent appearance of p-
I
WO 97/01338 PCT/US96/10778 nitroaniline. sar-PR-pna was used to assay human a-thrombin (Km= 125 gM) and bovine trypsin (Km=125 gM). p-Nitroanilide substrate concentration was determined from measurements of absorbance at 342 nm using an extinction coefficient of 8270 cm- 1 M-1.
In certain studies with potent inhibitors (Ki 10 nM) where the degree of inhibition of thrombin was high, a more sensitive activity assay was employed. In this assay the iate of thrombin catalyzed hydrolysis of the fluorogenic substrate Z-GPR-afc (Km=27 pM) was determined from the increase in fluorescence at 500 nm (excitation at 400 nm) associated wi:h production of 7-amino-4-trifluoromethyl coumarin.
Concentrations of stock solutions of Z-GPR-afc were determined from measurements of absorbance at 380 nm of the 7-amino-4-trifluoromethyl coumarin produced upon complete hydrolysis of an aliquot of the stock solution by thrombin.
Activity assays were performed by diluting a stock solution of substrate at least tenfold to a final concentration 0.1 Km into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (Vo) or presence of inhibitor (Vi) were measured.
Assuming competitive inhibition, and that unity is negligible compared and (where and e respectively represent the total concentrations, of substrate, inhibitor and enzyme), the equilibrium constant (Ki) for dissociation of the inhibitor from the enzyme can be obtained from the dependence of Vo/Vi on shown in equation 1.
Vo/Vi 1 [I]/Ki (1) The activities shown by this assay indicate that the compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, and reocclusion or restenosis of recanalized
I
WO 97/01338 PCT/US96/10778 -91 vessels. Compounds of Examples 1-4 inhibit human thrombin with Ki values less than 100 nM and inhibit human trypsin with Ki values greater than 500 nM.
EXAMPLE LI IN VIVO STUDIES TO MEASURE TIIROMBOTIC OCCLUSIONS Applicants have conducted in vivo studies of the compounds claimed herein using the following rat ferric chloride assay similarly as described in Thrombosis Research, No. 60, page 269(1990) by Kurtz et al.
In the assay used to determine in vivo activity of the thrombin inhibitors or the invention. Male Sprague-Dawley rats (body weights 200-350 grams) were anesthetized with dial-urethane solution (0.1 ml/100 gm body weight and a lateral tail vein was cannulated with a 23 gauge needle connected to a 12 inch length of PE50 tubing.
The tubing was attached to a 3-way valve by a tubing adapter. Saline (control) or test compound, as appropriate, was administered via the tail vein catheter. A tracheostomy was performed with a 0.75 inch length of PE205 tubing. The right carotid artery was exposed and a 1.3 mm diameter Doppler flow probe was placed on the vessel. Body temperature was maintained at 37 0 C using a heat lamp.
Rats (8-10/group) were randomized to continuous intravenous infusions of saline or test compound administered via the tail vein at a rate of 0.028 ml/min. Treatment infusions were initiated 120 min before the placement of a 3 mm square piece of Whatman No. 1 filter paper saturated with 35% FeCI3 onto the exposed carotid artery distal to the flow probe. Treatment infusions were continued for an additional 60 minutes after the application of FeCl3 (total infusion duration 180 minutes) if thrombotic occlusions did not occur, or were terminated 30 minutes after thrombotic occlusion of the vessel. Time to occlusion was defined as the time from application of FeCI3 to thrombotic occlusion of the vessel. At the termination of the study ~i C 'C -P I WO 97/01338 WO 9701338PCTIUS96/1 0778 92 minutes after application of FeCl3 in animals which did not occlude, or at minutes after thrombotic occlusion), 3 ml blood samples were drawn by cardiac puncture into 0.3 ml of 3.8% sodium citrate.
The results show that the compounds of the invention are useful in preventing thrombotic occlusions.
EXAMPLE LII1 Tablet Preparation Tablets containing 25.0, 50.0, a-nd 100.0 mg, respectively, of the following active compounds are prepared as illustrated below: 3-Benzylsulfonylamino-6-methyl- I -(4-methylenecarboxamidomethyl- Iamidi nopiperidinyl )-2-pyridinone, 3-(2-Phenylethylamino)-6-methyl- 1 -(methylenecarboxamido-trans-4aminocyciohexy Imethyl )-2-pyridinone, 3-Benzylsulfonylamino-6-methyl- 1 -(methylenecarboxamido-trans-4aminocyc lohexylImethyl])-2-pyri di none, 3-Benzylsulfonylaminio-6-methyl- I amidomethylpyridiriyl)-2-pyridinone.
TABLE FOR DOSES CONTAINING FROM 100MG OF THE ACTIVE COMPOUND Amount-mg Active Compound 25.0 50.0 100.0 Micro crystalline cellulose 37.25 100.0 200.0 Modified food corn starch 3.542 37.25 4.25 8.5 WO 97/01338 PCT/US96/10778 -93- Magnesium stearate 0.50 0.75 All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.
EXAMPLE LIV An intravenous dosage form of the above-indicated active compound is prepared as follows: Active Compound 0.5-10.0mg Sodium Citrate 5-50mg Citric Acid 1- Sodium Chloride 1-8mg Water for Injection (USP) q.s. to 1 ml Utilizing the above quantities, the active compound is dissolved at room temperature in a previously prepared solution of sodium chloride, citric acid, and sodium citrate in Water for Injection (USP, see page 1636 of United States Pharmacopeia/National Formulary for 1995, published by United States Pharmacopeial Convention, Inc., Rockville, Maryland, copyright 1994.
~p
Claims (23)
1. A compound having the formula: C W~ *0* *S 00 0 0 0000 41000 0 0*0 wherein W is RIOCO, RICO, R 1 S0 2 (Rl)il(CH 2 )flNHqCO, where n is 0-4, in is 1 or 2, arid q is 0 or 1, with the proviso that where n is 1-4, q is I and i is I, and where n is 0, mn is I or 2, and qi is 0 or 1, and with the further proviso that where n is 0, mn is 2 and qI is 0, RI can be the same Or different; RI is R 2 (CJ-I9n, where n is 0-4, (R 2 )(OR 2 )CI-I(CH 1 where p is 1-4, (R 2 2 CH(CH2)n, where n is 0-4 and R 2 can be thie samne or different, and wherein can also be a ring substitucnt on CHi represented by C 3 7 cycloalkyl, C 7 1 bicyclic 2o a~kyl, or a 5- to 7-membered mono- or bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to three heteroatorns selected From thle group consisting of N, 0 and S, and R 2 where in p is 1-4, 00 0 0 0* 0 0 00 N hI 0 14111 WO 97/01338 PCT/US96/10778 R 2 is hydrogen, phenyl, unsubstituted or substituted with one or more of C 1- 4 linear or branched alkyl, C1-4 linear or branched alkoxy, halogen, trifluoromethyl, hydroxy, COOH, or CONH2, naphthyl, biphenyl, a 5- to 7- membered mono- or a 9- to 10-membered bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to three heteroatoms selected from the group consisting of N, O and S, COOR 6 Cl-4 linear or branched alkyl, C3-7 cycloalkyl, or C7-12 bicyclic alkyl; R 3 is hydrogen, Cl-4 linear or branched alkyl, C3-7 cycloalkyl, or trifluoromethyl; A is chosen from one of the following Radicals: NH 2 R NH2 NY N H vYo 4 N xAr j trans R 4 I III rV wherein R 4 and R 5 are independently H, C1-4 linear or branched alkyl or alkoxy; C3-C7 cycloalkyl; halogen; or trifluoromethyl; WO 97/01338 PCT/US96/10778 -96- Y is hydrogen, hydroxy, or CN; R 6 is hydrogen, or Cl-4 linear or branched alkyl, and pharmaceutically acceptable salts thereof.
2. The compound of Claim I wherein W is R 1 or R 1 S02, and pharmaceutically acceptable salts thereof.
3. The compound of Claim 2 wherein R1, by itself or in R 1 S02, is R 2 (CH2)n, or (R 2 )2CH(CH2)n, phenyl, or (phenyl)2-CH, and pharmaceutically acceptable salts thereof.
4. The compound of Claim I wherein R 3 is Cl-4 linear or branched alkyl, and pharmaceutically acceptable salts thereof.
The compound of Claim 4 wherein R 3 is methyl, and pharmaceutically acceptable salts thereof.
6. The compound of Claim 1 wherein R 4 is CI-4 linear or branched alkyl and R 5 is methyl or hydrogen, and pharmaceutically acceptable salts thereof.
7. The compound of Claim 6 wherein R 4 is methyl and R 5 is methyl or hydrogen, and pharmaceutically acceptable salts thereof.
8. The compound of Claim 7 wherein R 4 is methyl and R 5 is hydrogen, and pharmaceutically acceptable salts thereof. WO 97/01338 PCT/US96/10778 -97-
9. The compound of Claim 1 wherein said radical A is Radical fi, and pharmaceutically acceptable salts thereof.
The compound of Claim I wherein said radical A is Radical II, and pharmaceutically acceptable salts thereof.
11. The compound of Claim 1 wherein said radical A is Radical IV, and pharmaceutically acceptable salts thereof. 0
12. The compound of Claim 1 selected from: S, 02 H 0 H 'N H2 H HN 'o N 0 NH2 N J H 0 H H H H 2 N N 0 N^ a WO 97/01338 WO 9701338PCT[US96/10778 98 0 NH 2 H2 H NH H 0 H N H s NI N-N N 02 0 o NH 2 H 0H SNJ N N 0l2 0 0 H3-~ N H 2 H 0H Cl s ,NJ N N C'02 I0 WO 97/01338 WO 9701338PCTJUS96/1O 778 99 N INH 2 H 0H 'SN N -"yN 02 Jl 0 S, 02 NH 2 Hl 0 H H N N j S JN 020 N NH 2 H0 H N NH s-NJN N 02 0 H0 H ",CNH 2 N IN-lN 0 WO 97/01338 WO 9701338PCTIUS96/ 10778 -100- o N NH 2 H 0H S' N N 0~2 Kt and pharmaceutically acceptable salts thereof.
13. The compound of Claim I selected from: o N NH 2 S, N- NN 02 0 NH 2 H 0 H 'NH H2 H and pharmaceutically acceptable salts thereof.
14. The compound of Claim I wherein said heterocyclic group is selected from: piperidinyl, piperazinyl, 2-oxopiperazinyl, 2- oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4- piperidonyl, pyr-rolidinyl, pyrazolyl, pyrazolidinyl, i-midazolyl, imidazolinyl, irnidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indoly], quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, th ienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxidc, thiamorpholinyl sulfone, and oxadiazolyl.
A 3-amino-l-(methylenecarboxamido)-2-pyridinone derivative or a 3-amido-l- (methylenecarboxamido)-2-pyridinone derivative, substantially as hereinbefore described with reference to any one of Examples I to L.
16. A pharmaceutical composition comprising a compound of any one of claims 1 to 15 and a pharmaceutically acceptable carrier.
17. A pharmaceutical composition substantially as hereinbefore described with reference to Example LIII or LIV.
18. A method for inhibiting thrombin in blood in a mammal requiring said inhibition, comprising adding to the blood of said mammal a compound of any one of claims 1 to 15 or a composition of claim 16 or 17 in an amount which effectively inhibits said thrombin in said blood.
19. A method for inhibiting formation of blood platelet aggregates in blood in a mammal requiring said inhibition, comprising adding to the blood of said mammal a compound of any one of claims 1 to 15 or a composition of claim 16 or 17 in an amount which effectively inhibits said blood platelet aggregate formation.
A method for inhibiting thrombus formation in blood in a mammal requiring said inhibition, comprising adding to the blood of said mammal a compound of any one of 20 claims 1 to 15 or a composition of claim 16 or 17 in an amount which effectively inhibits said thrombus formation.
21. The use of a compound of any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for lnhibiting thrombin, inhibiting thrombus formation, treating thrombus formation, or preventing thrombus formation in a mammal.
22. A compound of any one of claims 1 to 15 or i ar:-aceutically acceptable salt thereof when used for the inhibition of throminb., ;i!:'ition of thr,,i.bus formation, the treatment of thrombus formation, or the prt%ention of thrombus formation in a mammal requiring said inhibition, treatment or prevention.
23. A process for preparing a 3-amino-l-(methylenecarboxamido)-2-pyridinone derivative or a 3-amido-l-(methylenecarboxamido)-2-pyridinone derivative, substantially as hereinbefore described with reference to any one of Examples I to L. Dated 22 January, 1999 Merck Co., Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON IN LIlFF10347 ktnl
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56095P | 1995-06-27 | 1995-06-27 | |
| US60/000560 | 1995-06-27 | ||
| US381895P | 1995-09-15 | 1995-09-15 | |
| US60/003818 | 1995-09-15 | ||
| GB9603450 | 1996-02-19 | ||
| GBGB9603450.9A GB9603450D0 (en) | 1996-02-19 | 1996-02-19 | Pyridinone thrombin inhibitors |
| PCT/US1996/010778 WO1997001338A1 (en) | 1995-06-27 | 1996-06-24 | Pyridinone-thrombin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6391796A AU6391796A (en) | 1997-01-30 |
| AU703744B2 true AU703744B2 (en) | 1999-04-01 |
Family
ID=27268133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU63917/96A Ceased AU703744B2 (en) | 1995-06-27 | 1996-06-24 | Pyridinone-thrombin inhibitors |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0835109A4 (en) |
| JP (1) | JPH11508558A (en) |
| AU (1) | AU703744B2 (en) |
| CA (1) | CA2224437A1 (en) |
| WO (1) | WO1997001338A1 (en) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5872138A (en) * | 1996-09-13 | 1999-02-16 | Merck & Co., Inc. | Thrombin inhibitors |
| US6194435B1 (en) | 1996-10-11 | 2001-02-27 | Cor Therapeutics, Inc. | Lactams as selective factor Xa inhibitors |
| US6262047B1 (en) | 1996-10-11 | 2001-07-17 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
| US6369080B2 (en) | 1996-10-11 | 2002-04-09 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
| US6063794A (en) | 1996-10-11 | 2000-05-16 | Cor Therapeutics Inc. | Selective factor Xa inhibitors |
| US5869487A (en) * | 1996-10-24 | 1999-02-09 | Merck & Co., Inc. | Pyrido 3,4-B!pyrazines for use as thrombin inhibitors |
| AU715305B2 (en) * | 1996-10-24 | 2000-01-20 | Merck & Co., Inc. | Thrombin inhibitors |
| US6017934A (en) * | 1997-01-22 | 2000-01-25 | Merck & Co., Inc. | Thrombin inhibitors |
| JP2001508796A (en) * | 1997-01-22 | 2001-07-03 | メルク エンド カンパニー インコーポレーテッド | Thrombin inhibitors |
| US5792779A (en) * | 1997-02-19 | 1998-08-11 | Merck & Co., Inc. | Pyridinone thrombin inhibitors |
| US5932606A (en) * | 1997-03-24 | 1999-08-03 | Merck & Co., Inc. | Pyrazinone, pyridinone, piperidine and pyrrolidine thrombin inhibitors |
| CA2283704A1 (en) * | 1997-03-24 | 1998-10-01 | Merck & Co., Inc. | Thrombin inhibitors |
| AU6896398A (en) | 1997-04-14 | 1998-11-11 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
| AU6896298A (en) | 1997-04-14 | 1998-11-11 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
| US6133256A (en) * | 1997-04-14 | 2000-10-17 | Cor Therapeutics Inc | Selective factor Xa inhibitors |
| JP2002513412A (en) | 1997-04-14 | 2002-05-08 | シーオーアール セラピューティクス インコーポレイテッド | Selective factor Xa inhibitor |
| US6333321B1 (en) | 1997-08-11 | 2001-12-25 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
| US6228854B1 (en) | 1997-08-11 | 2001-05-08 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
| US6218382B1 (en) | 1997-08-11 | 2001-04-17 | Cor Therapeutics, Inc | Selective factor Xa inhibitors |
| EP1017393A4 (en) * | 1997-09-05 | 2002-01-23 | Merck & Co Inc | Pyrazinone thrombin inhibitors |
| US6011038A (en) * | 1997-09-05 | 2000-01-04 | Merck & Co., Inc. | Pyrazinone thrombin inhibitors |
| US6087373A (en) * | 1997-09-23 | 2000-07-11 | Merck & Co., Inc. | Thrombin inhibitors |
| US6133297A (en) * | 1997-09-30 | 2000-10-17 | Merck & Co., Inc. | Thrombin inhibitors |
| CN1125051C (en) * | 1997-11-26 | 2003-10-22 | 三维药物公司 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors |
| AU751412B2 (en) | 1997-11-26 | 2002-08-15 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors |
| AU741766B2 (en) * | 1997-12-01 | 2001-12-06 | Merck & Co., Inc. | Thrombin inhibitors |
| CA2321146A1 (en) * | 1998-02-17 | 1999-08-19 | Nippon Kayaku Kabushiki Kaisha | Novel acetamide derivative and use thereof |
| US6147078A (en) * | 1998-05-19 | 2000-11-14 | Merck & Co., Inc. | Pyrazinone thrombin inhibitors |
| JP2002516326A (en) * | 1998-05-26 | 2002-06-04 | メルク エンド カムパニー インコーポレーテッド | Imidazopyridine thrombin inhibitors |
| DE69926884T2 (en) | 1998-06-11 | 2006-06-14 | Johnson & Johnson Pharm Res | PYRAZINE PROTEASE INHIBITORS |
| ES2209337T3 (en) | 1998-08-14 | 2004-06-16 | Pfizer Inc. | ANTITROMBOTIC AGENTS. |
| EP1117660A4 (en) * | 1998-09-28 | 2002-01-09 | Merck & Co Inc | Thrombin inhibitors |
| EP1124822A4 (en) | 1998-10-30 | 2002-04-03 | Merck & Co Inc | Thrombin inhibitors |
| AU752186B2 (en) | 1998-10-30 | 2002-09-12 | Merck & Co., Inc. | Thrombin inhibitors |
| FR2786482B1 (en) * | 1998-11-27 | 2002-08-09 | Synthelabo | NOVEL 2-PYRIDONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| AR023510A1 (en) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | A TEAM OF PARTS, PHARMACEUTICAL FORMULATION AND USE OF A THROMBIN INHIBITOR. |
| US6239132B1 (en) | 1999-04-23 | 2001-05-29 | Merck & Co., Inc. | Thrombin inhibitors |
| US6750342B1 (en) | 1999-05-19 | 2004-06-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
| US6716838B1 (en) | 1999-05-19 | 2004-04-06 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
| PL352403A1 (en) * | 1999-05-19 | 2003-08-25 | Pharmacia Corp | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade |
| EP1586565A1 (en) * | 1999-05-19 | 2005-10-19 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
| US6458952B1 (en) | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
| US6653316B1 (en) | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
| US7015230B1 (en) | 1999-05-19 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
| US6664255B1 (en) | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
| US6867217B1 (en) | 1999-05-19 | 2005-03-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade |
| PL352368A1 (en) * | 1999-05-19 | 2003-08-25 | Pharmacia Corp | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
| EP1189901A1 (en) * | 1999-05-27 | 2002-03-27 | 3-Dimensional Pharmaceuticals, Inc. | Oxazaheterocycles as protease inhibitors |
| WO2000074682A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Thrombin inhibitors |
| UA58636C2 (en) * | 1999-06-04 | 2003-08-15 | Мерк Енд Ко., Інк. | Pyrazinone thrombin inhibitors, pharmaceutical composition, method for treatment conditions caused by thrombus formation |
| DE60005351D1 (en) | 1999-07-09 | 2003-10-23 | Dimensional Pharm Inc | HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING PRODUCTS |
| CN1373755A (en) | 1999-09-13 | 2002-10-09 | 三维药物公司 | Azacycloalkanone serine protease inhibitors |
| AU2044401A (en) | 1999-11-23 | 2001-06-04 | Merck & Co., Inc. | Pyrazinone thrombin inhibitors |
| AU2001243598A1 (en) | 2000-03-13 | 2001-09-24 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade |
| EP1267876A1 (en) | 2000-03-23 | 2003-01-02 | Merck & Co., Inc. | Thrombin inhibitors |
| AU2001251315A1 (en) * | 2000-04-05 | 2001-10-23 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| CA2405561A1 (en) | 2000-04-05 | 2001-10-18 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| US6506754B1 (en) | 2000-04-14 | 2003-01-14 | Corvas International, Inc. | Non-covalent thrombin inhibitors |
| AU2001255399A1 (en) * | 2000-04-14 | 2001-10-30 | Corvas International, Inc. | Pyridine and pyrazine derivatives as thrombin inhibitors |
| AU2001255408A1 (en) * | 2000-04-14 | 2001-10-30 | Corvas International, Inc. | Tetrahydro-azepinone derivatives as thrombin inhibitors |
| US20040171616A9 (en) | 2000-04-17 | 2004-09-02 | South Michael S. | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| AU2001278927A1 (en) | 2000-07-17 | 2002-01-30 | 3-Dimensional Pharmaceuticals, Inc. | Cyclic oxyguanidine pyrazinones as protease inhibitors |
| JP2004505956A (en) | 2000-08-04 | 2004-02-26 | ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド | Cyclic oxyguanidine protease inhibitor |
| UA75093C2 (en) | 2000-10-06 | 2006-03-15 | Dimensional Pharm Inc | Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors |
| WO2002042272A2 (en) * | 2000-11-20 | 2002-05-30 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| US7119094B1 (en) | 2000-11-20 | 2006-10-10 | Warner-Lambert Company | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade |
| US7015223B1 (en) | 2000-11-20 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade |
| US6777431B2 (en) * | 2001-07-13 | 2004-08-17 | Corvas International, Inc. | Non-convalent thrombin inhibitors |
| CA2462305A1 (en) | 2001-10-03 | 2003-04-10 | Michael S. South | 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| CA2462645A1 (en) | 2001-10-03 | 2003-11-13 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| SI21097A (en) | 2001-12-04 | 2003-06-30 | Univerza V Ljubljani | Thrombine inhibitors |
| US7550474B2 (en) | 2003-04-10 | 2009-06-23 | Johnson & Johnson Pharmaceuticals Research & Development, L.L.C. | Substituted phenyl acetamides and their use as protease inhibitors |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| EP1893601A1 (en) * | 2005-06-17 | 2008-03-05 | AstraZeneca AB | Thrombin inhibiting 2-oxo-1, 2, 5, 6-tetrahydropyridine derivatives |
| BRPI0812766B8 (en) * | 2007-06-29 | 2022-06-28 | Dow Agrosciences Llc | PROCESS FOR PREPARATION OF 4-ALKOXY-1,1,1-TRIFLUORINE-3-BUTEN-2-ONAS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9207145D0 (en) * | 1991-04-18 | 1992-05-13 | Ici Plc | Heterocyclic amides |
| TW223629B (en) * | 1992-03-06 | 1994-05-11 | Hoffmann La Roche | |
| WO1994017817A1 (en) * | 1993-02-12 | 1994-08-18 | Corvas International, Inc. | Inhibitors of thrombosis |
-
1996
- 1996-06-24 WO PCT/US1996/010778 patent/WO1997001338A1/en not_active Application Discontinuation
- 1996-06-24 JP JP9504499A patent/JPH11508558A/en active Pending
- 1996-06-24 CA CA002224437A patent/CA2224437A1/en not_active Abandoned
- 1996-06-24 AU AU63917/96A patent/AU703744B2/en not_active Ceased
- 1996-06-24 EP EP96923399A patent/EP0835109A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2224437A1 (en) | 1997-01-16 |
| JPH11508558A (en) | 1999-07-27 |
| WO1997001338A1 (en) | 1997-01-16 |
| EP0835109A4 (en) | 1999-02-03 |
| AU6391796A (en) | 1997-01-30 |
| EP0835109A1 (en) | 1998-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU703744B2 (en) | Pyridinone-thrombin inhibitors | |
| US5668289A (en) | Pyridinone thrombin inhibitors | |
| AU720616B2 (en) | Pyridinone thrombin inhibitors | |
| US5792779A (en) | Pyridinone thrombin inhibitors | |
| EP0820287B1 (en) | Thrombin inhibitors | |
| AU728006B2 (en) | Thrombin inhibitors | |
| US5869487A (en) | Pyrido 3,4-B!pyrazines for use as thrombin inhibitors | |
| EP0934064B1 (en) | Thrombin inhibitors | |
| US6534510B2 (en) | Thrombin inhibitors | |
| AU6161399A (en) | Thrombin inhibitors | |
| EP0858262B1 (en) | Thrombin inhibitors | |
| US5798377A (en) | Thrombin inhibitors | |
| US5932606A (en) | Pyrazinone, pyridinone, piperidine and pyrrolidine thrombin inhibitors | |
| US5792761A (en) | Thrombin inhibitors | |
| EP0949921B1 (en) | Thrombin inhibitors | |
| US6004976A (en) | Thrombin inhibitors | |
| EP1039907A1 (en) | Thrombin inhibitors |